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9ABSTRACT
Transforming growth factor-β (TGF-β) is a potent growth inhibitor of mammalian cells,
particularly those of epithelial or endothelial origin. The growth inhibitory activity of TGF-β is
mediated by retinoblastoma tumor suppressor protein (pRb) functioning in its underphosphorylated
form to arrest the cell cycle in G1-phase. TGF-β regulates the phosphorylation status of pRb by
inhibiting the activity of cyclin dependent kinase (Cdk) -complexes that phosphorylate pRb.
In the present study we found novel mechanisms of regulation of Cdk inhibitors (Cdkis) p15 and
p27 by TGF-β. In addition, overexpression of Ras oncoprotein was found to induce p21 Cdk inhibitor
by transcriptional and posttranscriptional mechanisms. The Cdk inhibitor p15 was found to have an
alternative spliced mRNA form termed as p10. p10 mRNA is ubiquitously expressed in normal and
tumor cell lines, and its expression is induced by TGF-β1 similarly to p15. Unlike p15, p10 did not
associate with G1-specific Cdks 4 or 6. Further, TGF-β was found to induce accumulation of a
subpopulation of p27 Cdk inhibitor in Mv1Lu cells with an exclusively nuclear localization. In
contrast to the rest of the p27 pool, it lacks association with Cdks and cyclins. These results suggest
further complexity of TGF-β growth regulation in Mv1Lu cells.
TGF-β growth regulation was also studied by using hepatocyte growth factor (HGF) as an
antagonist of TGF-β. HGF counteracts the TGF-β mediated growth inhibition and induces Mv1Lu
cell proliferation. We found that HGF prevents TGF-β growth arrest mainly by preventing the
downregulation of Cdk6 levels by TGF-β suggesting that the regulation of Cdk6 is important for
TGF-β growth arrest. The increased Cdk6 levels associate with part of p27 and prevent p27 from
binding to and inhibiting the activity of Cdk2-cyclin E-complexes leading to rescue of Cdk2-
asociated kinase activity. In addition, cyclin D-associated kinase activity is partially restored,
although p15 Cdk inhibitor is still associated at elevated levels with Cdk6. As a consequence pRb
is phosphorylated and cell cycle can progress from G1 to S-phase.
As a conclusion, the study suggests further complexity of G1 and G1/S-phase specific Cdk-
complex regulation by TGF-β.
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 A. INTRODUCTION
A 1. Mammalian cell cycle
The purpose of the cell cycle is to multiply cells and to ensure that events of DNA replication and
cell division occur in good order with correct timing. The mammalian cell cycle can be divided into
four different phases (Fig. 1). The G1 (gap-1) -phase involves cellular growth and active protein
synthesis. In S (synthesis) -phase DNA is replicated and in G2 (gap-2) -phase the nucleus prepares
for cell division. In mitosis (M) the replicated chromosomes are divided into two daughter nuclei
followed by the actual cytokinesis, where the cell divides into two daughter cells. Terminally
differentiated or mitogen-deprived cells are withdrawn from cell cycle into a so-called G0-phase,
from which they can re-enter in some instances into the mitotic cycle through G1-phase. Mammalian
cells receive various signals from extracellular growth factors, some of which stimulate growth,
while others inhibit mitogenesis, induce differentiation or provide positional information. Based on
these different signals the cells have to make a decision of whether proliferate or not. The cells are
sensitive to extracellular stimuli until they reach a restriction point in late G1-phase, after which they
can complete the division cycle without extracellular signals (Pardee, 1989).
Cell cycle progression of eukaryotic cells is controlled by the sequential activation of cyclin–
cyclin dependent kinase (Cdk) complexes (Fig. 1). Formation of the complexes and regulation of
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Fig. 1 The mammalian cell cycle is driven by the activity of several Cdk-cyclin complexes. The
activities of Cdk4/6 in complex with D-type cyclins together with Cdk2 in complex with cyclin E
are required for the G1-S transition. The best studied target of these Cdk complexes is pRb.Underphosphorylated pRb forms a repressor complex with E2F family of transcription factors and
prevents transcription of E2F target genes. When phosphorylated pRb dissociates from E2F, and
transcription of genes required for S-phase transition can begin (see text for details).
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their activity is highly specific, and distinct complexes drive cell cycle progression in G1, G1/S and
S-phases, and in mitosis (reviewed in Morgan, 1995; Pines, 1995; Sherr, 1996). The G1 progression
is regulated by D-type cyclins (D1-3) that form complexes with Cdk4 or Cdk6 and later in G1 by
cyclin E in complex with Cdk2 (reviewed by Sherr, 1994). Additionally, a Cdk3-associated kinase
activity is found to be induced during G1-S transition (Meyerson et al., 1992; van den Heuvel and
Harlow, 1993).
Retinoblastoma/E2F-pathway as a controller of G1-progression
Retinoblastoma tumor suppressor protein (pRb) is thought to be an important regulator of the G1
restriction point in mammalian cells, and its activity is vital for orderly cell cycle progression. pRb
is the most studied substrate of the G1 and G1/S specific cyclin-Cdk-complexes. The Rb gene is
mutated or deleted in a variety of tumors including retinoblastoma, osteosarcoma, small-cell lung
carcinoma, and bladder cancer (reviewed by Weinberg 1991; 1995). pRb is a nuclear phosphoprotein
whose activity is regulated by multiple phosphorylations. Different lines of evidence indicate that
hypo- and/or unphosphorylated form of pRb restricts cellular growth. First, DNA tumor virus
oncoproteins, such as SV40 large T antigen, adenoviral E1A and papillomaviral E7, specifically bind
and harvest unphosphorylated, but not phosphorylated, forms of pRb (Whyte et al., 1988; DeCaprio
et al., 1988; Dyson et al., 1989a, b; Munger et al., 1989; Egan et al., 1989). Second, the
hypophosphorylated form of pRb binds several cellular proteins such as the E2F family of
transcription factors (Chellappan et al., 1991), MyoD and c-Abl (reviewed by Wang et al., 1994).
Binding to pRb prevents E2F from activating the transcription of its target genes, which are
required for the initiation of the S-phase. When phosphorylated, pRb can no longer associate with
E2F (Fig. 1; Chellappan et al., 1991). The E2F transcription factor is actually a heterodimer
composed of two partners, E2F and DP. At least five distinct E2F subunits are known. They all
recognize a target sequence present in the promoters of several genes important for cell growth
control and S-phase entry, such as c-myc, B-myb, Cdc2, thymidine kinase and E2F-1 itself (reviewed
by LaThangue 1994; Weinberg, 1995; Cobrinik, 1996). Of the five E2F family members, pRb binds
preferentially to E2Fs 1-3, and also E2F-4 in some cell types, whereas pRb family members p107
and p130 associate with E2Fs 4-5 (reviewed by Weinberg, 1996; Ezhevsky et al., 1997). Rather than
blocking E2F transcriptional activity, studies suggest that pRb-E2F complex bound to a promoter
region is an active transcriptional repressor (reviewed by Brehm and Kouzarides, 1999). Competi-
tion of pRb-E2F transcriptional repressor complex by stable overexpression of a mutant E2F
containing only the DNA binding domain, but lacking pRb binding and transcriptional transactivator
sites, can prevent G1 arrest suggesting that active repressor complexes formed by pRb and E2F are
required for the G1 arrest (Zhang et al., 1999).
In G1 and G1/S-phases pRb is phosphorylated by cyclin D- and E-associated Cdks at several
specific sites (reviewed by Taya, 1997). Cdk4-cyclin D-complexes have a different phosphorylation
consensus site than Cdk2-cyclinE/A-complexes (Kitagawa et al., 1996), and they phosphorylate pRb
on distinct sites (Zarkowska and Mittnacht, 1997). Furthermore, the phosphorylation of the specific
sites is required to inhibit the binding of SV40 large T antigen, c-Abl or E2F to pRb, suggesting that
the phosphorylations regulate different protein-protein interactions (Knudsen and Wang, 1996).
Although earlier studies suggested that overexpressed D- or E-cyclins can overcame pRb-mediated
suppression of proliferation (Hinds et al., 1992; Dowdy et al., 1993; Ewen et al., 1993a), more recent
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Control of cell cycle progression by G1 and G1/S specific Cdk-cyclin complexes
Inadequate activation of G1 and G1/S specific Cdk-cyclin complexes can lead to premature entry
into S-phase independently of signals that restrict cellular growth such as growth factors or DNA
damage. Mouse embryo fibroblasts lacking Rb have shortened G1 phase and elevated cyclin E
expression (Herrera et al., 1996a). Similarly, overexpression of the G1 and G1/S specific D- and E-
type cyclins in fibroblasts shortens the G1-phase, decreases cell size and decreases the dependency
of the cell of mitogens, suggesting that they are rate limiting for G1 progression (Ohtsubo and
Roberts, 1993; Quelle et al., 1993; Resnitzky et al., 1994).
D-type cyclins
The three different D-type cyclins (D1 to D3) have distinct, although overlapping, expression
patterns in tissues (Matsushime et al., 1991; Inaba et al., 1992; Kiyokawa et al., 1992; Motokura et
al., 1992; Ajchenbaum et al., 1993, Sicinsky et al., 1995, 1996; Lukas et al., 1995a). The expression
of the D-type cyclins is induced in G1 by mitogenic growth factors, and they are synthesized as long
as the stimulation persists. Their levels oscillate moderately during the cell cycle being highest in G1-
phase (Kiyokawa et al., 1992; Motokura et al.,  1992; Won et al., 1992; Ajchenbaum et al., 1993).
D-type cyclins are highly unstable proteins (T1/2 < 30 min; Matsushime et al., 1992) and like many
other cell cycle regulatory proteins cyclin D1 has been shown to be degradated via the proteasome
pathway (Diehl et al., 1997; reviewed by Pagano, 1997). Mitogen withdrawal in G1-phase leads to
rapid degradation of the D-type cyclins and to failure of the cells to enter S-phase. Later in cell cycle
degradation of D-type cyclins does not have an effect on cell cycle progression  (Matsushime et al.,
1991). Cyclin D-associated kinase activity is first detected in mid-G1 and increases towards G1/S
boundary (Matsushime et al., 1994; Meyerson and Harlow 1994). Microinjection of cyclin D1 or D2
antibodies into normal fibroblasts or lymphocytes, respectively, in early G1 prevents their entry into
S-phase but fails to do so near the G1/S transition, indicating that the cyclin D-associated activity is
needed in middle to late G1 (Baldin et al., 1993; Quelle et al., 1993; Lukas et al., 1995a, 1995b).
Homozygous deletion of Cyclin D1 or D2 genes does not compromise development of viable
animals. Mice lacking cyclin D1 or D2 have focal developmental anomalies such as impaired
development of all layers of the retina and the mammary gland during pregnancy in the cyclin D1-
deficient animals (Fantl et al., 1995; Sicinski et al., 1995). Cyclin D2-deficient female mice are steril
due to inability of the granulosa cells to proliferate (Sicinski et al., 1996).
studies suggest that neither endogenous cyclin D- or E-associated activity alone is enough for Rb
inactivation. Several studies indicate that Cdk2-cyclin E-complexes are unable to phosphorylate
endogenous pRb unless it has been first phosphorylated by cyclin D-complexes (Resnitzky and
Reed, 1995; Leone et al., 1997; Lundberg and Weinberg, 1998). Similarly, ectopically expressed
human pRb is fully phosphorylated in yeast only in the presence of both cyclin D and E (or their yeast
homologues) (Hatakeyama et al., 1994). Endogenous cyclin D-complexes have been shown to
partially, but not fully phosphorylate pRb in G1 giving rise to a hypophosphorylated form of pRb
(Ezhevsky et al., 1997). This study also suggests that the hypophosphorylated pRb can still associate
with E2F and is thus active. Taken together these results indicate that a sequential activity of D-type
and E-type associated kinases is needed for inactivation of pRb in G1-S transition and cell cycle
progression.
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The activity of Cdk4 or 6-cyclin D complexes is required for pRb phosphorylation in G1
The main partners of D -type cyclins are Cdk4 and Cdk6 (Meyerson et al., 1991; Matsushime et
al., 1992, 1994; Meyerson and Harlow 1994), although in some cell types cyclins D2 and D3 have
been shown to associate with and activate also Cdk2 (Ewen et al., 1993a; Kato and Sherr, 1993;
Sweeney et al., 1997). Cdk4 and Cdk6 are two close homologues that have overlapping expression
patterns in different tissues (Meyerson et al., 1991, Matsushime et al., 1992, 1994; Meyerson and
Harlow 1994). Cdk4 and Cdk6 can be found both in nucleus and cytoplasm, and association with
cyclin D is needed for their nuclear transport (Diehl and Sherr, 1997). Only the nuclear complex
contains kinase activity, as shown with Cdk6-cyclin D3-complex (Mahony et al.,  1998).
The best studied substrate of G1 specific Cdks is pRb. The D-type cyclins, unlike cyclin E, bind
directly to pRb (Dowdy et al., 1993; Ewen et al., 1993a) and target it to Cdk4 (Kato et al., 1993).
Unlike Cyclin D2-Cdk2 complexes, cyclin D-Cdk4 or -Cdk6 complexes do not phosphorylate
histone H1 (Matsushime et al., 1992, 1994; Meyerson and Harlow 1994; Sweeney et al., 1997). It
is suggested that the substrate specificity can be modulated by both the Cdk and the cyclin subunit.
For instance, cyclin D1-Cdk4 complexes phosphorylated 38 and 24 kDa proteins while cyclin D3-
Cdk4 specifically phosphorylated proteins of 105, 102, 42 and 24 kDa in T-47D breast cancer cell
line lysates in vitro. Cyclin D3-Cdk6 complex, instead, did not phosphorylate the 24 kDa protein
(Sarcevic et al., 1997). These data also suggest that the functions of the different Cdk4/6-cyclin D
complexes are not redundant.
Several studies indicate that cyclin D-associated Cdk4 or Cdk6 kinase activity is dispensable in
cells lacking functional pRb suggesting that pRb is a key substrate for cyclin D-associated kinase
activity (Tam et al., 1994a; Lukas et al., 1994; 1995b; Medema et al., 1995; Parry et al., 1995).
However, cyclin D-associated kinases can target additional substrates such as pRb-related p107 and
p130 proteins (Beijersbergen et al.,  1995; Mayol et al.,  1995), and DMP1 transcription factor (Hirai
and Sherr, 1996). Additionally, nucleolin was found to be phosphorylated by Cyclin D3-Cdk4/6
complexes in T-47D cell lysates (Sarcevic et al.,  1997).
E-type cyclins
The expression of cyclin E is periodic, peaking in G1/S transition, where it assembles with Cdk2
(Dulic et al., 1992; Koff et al.,  1991, 1992). Similarly to the cyclin D family, the half-life of cyclin
E is short (approx. 30 min) and it is degradated via proteasome pathway after phosphorylation by
Cdk2 (Won and Reed, 1996). Like cyclin D antibodies, microinjection of cyclin E antibodies in G1-
phase, but not close to the G1/S transition, prevents entry of cells into S-phase (Ohtsubo et al., 1995).
Similarly to cyclin E, a recently cloned cyclin E2 associates with Cdk2 (Lauper et al., 1998; Zariwala
et al., 1999). The two E-type cyclins have somewhat different expression patterns in different tissues
(Zariwala et al., 1999). Cyclin E expression is regulated by pRb via E2F transcription factors
(Duronio and O’Farrell, 1995; Ohtani et al., 1995; Botz et al., 1996; Geng et al., 1996). Also
expression of Cyclin E2 seems to be negatively regulated by pRb, since expression of papilloma virus
oncoprotein E7 that inactivates pRb, increases the steady state levels of both E-type cyclins.
However, E6, which associates only with p53, upregulates only cyclin E2 suggesting that p53 may
be involved in cyclin E2 regulation (Zariwala et al., 1999).
Cdk2-cyclin E-complexes in G1/S-phase transition
Cdk2 is a more closely related to mitotic Cdc2 than to Cdk4 or 6 (Meyerson et al., 1991). Cdk2
associates with Cyclin E in G1/S-phase transition, and later in the S-phase with cyclin A. The Cdk2-
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cyclin E-complexes can phosphorylate histone H1, Rb, p107 and p130 (Hinds et al., 1992; Herrera
et al., 1996b; Woo et al., 1997; Castaño et al., 1998). Several lines of evidence suggest that pRb is
not the only important target of cyclin E-complexes. First, in contrast to cyclin D, cyclin E is needed
for S-phase entry in cells lacking functional pRb (Ohtsubo et al., 1995). Second, cyclin E overcomes
G1 arrest induced by mutant pRb lacking Cdk phosphorylation sites and dominant-negative mutant
DP-1, suggesting that cyclin E can induce S-phase without activating the pRb/E2F pathway (Lukas
et al., 1997). Third, cyclin E overexpression bypasses the G1 block induced by the Cdk4/6-inhibitor
p16 (Alevizopoulos et al., 1997). In addition, SV40 large T antigen fails to induce S-phase in the
presence of dominant-negative Cdk2 suggesting that Cdk2 has other substrates in addition to pRb
(Hofmann and Livingston, 1996).
Recent identification of novel Cdk2 substrates suggests that Cdk2 kinase activity regulates onset
of S-phase and DNA replication. NPAT (for nuclear protein mapped to Ataxia-telangiectasia locus)
was recently found to be a Cdk2-cyclin E substrate (Zhao et al., 1998). NPAT, as the name states,
is located next to ATM (Ataxia-telangiectasia mutated) gene in human chromosome 11. Overexpression
of NPAT in U2OS osteosarcoma accelerates S-phase entry by shortening the G1-phase. However,
there is no evidence so far that the phosphorylation of NPAT by Cdk2-cyclin E is needed for S-phase
entry (Zhao et al., 1998). Cdc6 is another novel substrate for Cdk2-complexes. Cdc6 is an essential
regulator of initiation of DNA replication, and its cellular localization is cell-cycle dependent.
Phosphorylation of Cdc6 by Cdk2-complexes removes Cdc6 from the nucleus and prevents re-
replication of DNA (Jiang et al., 1999; Petersen et al., 1999). Interestingly, Cdk2-cyclin E-activity
was also found to promote centrosome duplication in Xenopus egg extracts (Hinchcliffe et al., 1999;
Lacey et al., 1999).
2. Regulation of Cdk activity
The activity of mammalian Cdks is regulated by multiple mechanisms that include complex
formation with cyclin, stimulatory and inhibitory phosphorylations, and negative regulation through
association with Cdk inhibitory proteins.
Cdk activity requires cyclin binding and activating phosphorylation
The complex formation with cyclin subunit and stimulatory phosphorylation of a conserved
threonine residue (thr-160 in human Cdk2) are absolutely needed for the kinase activity of Cdks
(Ducommun et al., 1991; Gould et al., 1991; Desai et al., 1992; Solomon et al., 1992; Connell-
Crowley et al., 1993). In addition, cyclin association contributes to substrate specificity (Holmes and
Solomon, 1996; Sarcevic et al., 1997). A steric model of Cdk2-cyclin A complex indicates that the
association of cyclin subunit promotes the activity of the Cdk subunit by relieving blockage for
substrate binding and moving the ATP-binding site into the catalytic cleft. In addition, cyclin binding
exposes the thr-160 phosphorylation site of Cdk (Jeffrey et al., 1995). Phosphorylation of the
conserved thr-residue by CAK (cyclin activating kinase) is needed for the completion of the Cdk
activation process (Table 1). The thr-phosphorylation promotes further structural changes in the
Cdk-subunit leading to stabilization of the complex with cyclin and affecting the putative substrate
binding site (Russo et al., 1996a).
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Cdk7(MO15)-cyclin H complex has been suggested be the Xenopus and mammalian CAK, and
it was demonstrated to phosphorylate Cdc2, Cdk2 and Cdk4 in vitro (Table 1; reviewed by Harper
and Elledge, 1998). Cdk7-cyclin H complex and its S. cerevisiae homologue are part of the TFIIH
transcription complex and are needed for phosphorylation of C-terminal domain of RNA polymerase
II (Roy et al., 1994; Akoulitchev et al., 1995; Shiekhattar et al., 1995) raising the question whether
Cdk7-cyclin H is a true mammalian CAK. However, Cdk7 homologue in Drosophila is necessary
for CAK activity and is required for the activation of Cdc2 in vivo suggesting that Cdk7 is the CAK
in the multicellular organisms (Larochelle et al., 1998). Thr-dephosphorylation of Cdk2 and Cdc2
can be carried out by Kap-1 phosphatase, which removes the phosphate but only in the absence of
cyclin (Poon and Hunter, 1995).
Table 1. Regulation of mammalian Cdk activity by phosphorylations. See text for details and references.
Thr-phosphorylation
at thr-160 (Cdk2)
Tyr/thr-phopshorylation
at thr-14, tyr-15 (Cdk2)
Phosphorylating enzyme
Phosphatase
Effect on Cdk activity positive negative
Kap1
Wee1 and Mik1 homologues
Cdc25 family
CAK (Cdk7-cyclin H?)
Inhibitory tyrosine phosphorylation
Tyrosine phosphorylation is suggested to prevent premature kinase activation and to maintain it
within tightly regulated limits. Human Cdc2 and Cdk2 kinase activity is negatively regulated by
phosphorylation of thr-14 and tyr-15 residues (Table 1; Gu et al., 1992). Mutation of Cdk2 thr-14
and tyr-15 to alanine residues stimulates the kinase activity (Gu et al., 1992). Cdk4 and Cdk6, instead,
have only the tyrosine residue in this region (Matsushime et al., 1992; Meyerson et al., 1992). Thr-
14 and tyr-15 phosphorylation of Cdc2 prevents premature entry into mitosis (reviewed by Nurse,
1990; Solomon, 1993). The role of Cdk2 tyr-15 phosphorylation is less clear, and it is found to be
maximal in S and G2-phase cells (Gu et al., 1992; Sexl et al., 1999). In some cell types Cdk4 and/
or Cdk6 are tyrosine phosphorylated after UV- (Terada et al., 1995; Jinno et al., 1999) or TGF-β-
induced (Iavarone and Massagué, 1997) G1-arrest.
Wee1 and Mik1 family members of protein kinases co-operate in phosphorylating thr-14 and tyr-
15 of Cdc2 and Cdk2 (or their homologues) in yeast, Xenopus and human cells (Lundgren et al., 1991;
Müller et al., 1995; Watanabe et al., 1995). A Cdc25 phosphatase family removes the threonine and
tyrosine phosphorylations. Cdc25A and Cdc25C function in G1-S and G2-M transitions of human
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cells, respectively, and their activity is positively regulated by Cdk2-cyclin E and Cdc2-Cyclin B
mediated phosphorylation (Hoffmann et al., 1993, 1994; Jinno et al., 1994).
 Cyclin dependent kinase inhibitors
Cyclin dependent kinase inhibitors (Cdkis) are small proteins that bind to and inhibit the activity
of Cdk-cyclin complexes. Two families of Cdkis are found in mammalian cells, namely the p21- and
p16-related proteins (reviewed by Graña and Reddy, 1995; Sherr and Roberts, 1995). Members of
the p21 family are more universal Cdk inhibitors forming ternary complexes with G1, G1/S and to
some extent also with mitotic Cdks and cyclins (reviewed by Hengst and Reed, 1998). p16 family
members, in contrast, form binary complexes and inhibit only the activity of G1 specific Cdks 4 and
6 (reviewed by Carnero and Hannon, 1998).
p21 family
Structural motifs of p21 family
p21 family consists of three members: p21CIP1,WAF1,Sdi1 (El-Deiry et al., 1993; Gu et al., 1993; Xiong
et al., 1993a; Harper et al., 1993; Noda et al., 1994), p27KIP1 (Polyak et al., 1994a, b; Toyoshima and
Hunter 1994) and p57KIP2 (Matsuoka et al., 1995; Lee et al., 1995). The p21 family members associate
with and inhibit the activity of Cdk-cyclin complexes through their N-terminal domains that are more
conserved than the C-terminal domains (Fig. 2; Toyoshima and Hunter, 1994; Chen et al., 1995,
p21
p27 *
p57
Cdk NLS
*proline acidic
rich domains
PCNA binding
(164 aa)
Cdk/cyclin
(198 aa)
(316 aa) Cyclin
interaction
NLS
Fig. 2 Schematic representation of the p21 family members. Domains corresponding to Cdk, cyclin
and/or PCNA binding, nuclear localization signal (NLS) as well as proline and acidic rich areas of
p57 are shown. The asterisk (*) indicates the putative Cdc2 phosphorylation consensus site that in
at least p27 is phosphorylated by Cdk2. The total length of each human protein is indicated in amino
acids (aa). The figure is adapted from Lee et al., 1995. (The Cdk-cyclin interaction domains are
according to Russo et al., 1996b, the other domains are from Harper et al., 1993; Polyak et al., 1994b;
Lee et al., 1995; Matsuoka et al., 1995; Watanabe et al., 1998).
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1996a, b; Goubin and Ducommun 1995; Harper et al., 1995; Lee et al., 1995; Luo et al., 1995;
Matsuoka et al., 1995; Nakanishi et al., 1995; Fotedar et al., 1996).
The C-terminal halves of the different p21 family of Cdk inhibitors have different functions. p21
associates with proliferating cell nuclear antigen (PCNA) via the C-terminus (Chen et al., 1995,
1996b; Goubin and Ducummun 1995; Luo et al., 1995). PCNA is a subunit of DNA polymerase-δ,
which is the principal replicative DNA polymerase (reviewed by Celis et al., 1987). Binding of p21to
PCNA inhibits DNA replication (Flores-Rozas et al., 1994; Waga et al., 1994a; Chen et al., 1995),
but not PCNA-mediated nucleotide-excision repair (Li et al., 1996). Similar to p21, the C-terminal
domain of human p57 contains a short sequence that resembles the p21 PCNA-binding region, and
it can inhibit PCNA-dependent DNA synthesis in vitro and block the onset of S-phase in vivo
(Watanabe et al., 1998). Otherwise, the C-terminal domain as well as the N-terminal domain of p57
are more homologous to p27 than p21. Similar to p27, the C-terminal domain of p57 contains a
putative Cdk phosphorylation site (Lee et al., 1995; Matsuoka et al., 1995). Also p21 is a
phosphoprotein (Zhang et al., 1994; Dulic et al., 1998). In addition, the C-terminal domains of p21
and p27 contain an additional cyclin binding motif (Toyoshima and Hunter, 1994; Chen et al.,
1996a), importance of which is unclear. The C-terminal cyclin binding motif of p21 has a lower
affinity for cyclins than the N-terminal cyclin interaction domain (Chen et al., 1996a).
Viral oncoproteins negatively affect the function of p21 and p27 by binding to the C-terminal part.
Human papilloma virus E7 oncoprotein can block p21-mediated inhibition of Cdk activity and DNA
replication by associating with the carboxyl-terminal end on p21 (Funk et al., 1997; Jones et al.,
1997). Similarly, E7 inactivates p27 but whether the interaction is direct or depends on a third
protein(s) is unclear (Zerfass-Thome et al., 1996). In addition, the adenovirus E1A oncoprotein binds
to p27 strongly via the C-terminal domain of p27 and weakly via the N-terminal half (Mal et al.,
1996). This interaction overcomes the p27-mediated Cdk2-inhibition, since E1A can dislocate p27
from Cdk2 complexes in vitro and in vivo (Mal et al., 1996).
The additional functions described for p27 C-terminal part are not related to the ability of p27 to
inactivate G1 and G1/S specific Cdks. In contrast, the C-terminal domain of p27 has been indicated
to activate Cdc2 kinase activity during G2-M in synchronized culture of NIH 3T3 cells (Üren et al.,
1997). During the G2-M transition a variant of p27 that lacks aminoterminal half is induced. This C-
terminal p27 variant, when assayed in vitro, stimulates Cdc2 kinase activity (Üren et al., 1997). In
addition, the C-terminal half of p27 is able to induce proteolytic cleavage of cyclin A in vitro and in
vivo. The cleavage removes the mitotic destruction box of cyclin A, which leads to accumulation of
cyclin A. The truncated cyclin A retains associated kinase activity (Bastians et al., 1998).
The p21 family members are both negative and positive regulators of the Cdk-activity
Based on in vitro and overexpression studies p21, p27 and p57 were described initially as efficient
inhibitors of at least Cdk4-cyclin D, Cdk2-cyclin E and Cdk2-cyclin A -complexes, and to a lesser
extent mitotic Cdc2-cyclin B-complexes (Gu et al., 1993; Harper et al., 1993, 1995; Dulic et al.,
1994; Polyak et al., 1994a and b; Toyoshima and Hunter, 1994; Slingerland et al., 1994; Lee et al.,
1995; Matsuoka et al., 1995). However, growing evidence suggest that p21 family members are
efficient inhibitors of cyclin E- and A-complexes, whereas their association with cyclin D-
complexes is required for the normal function of the complexes.
Crystal structure of p27 bound to Cdk2-cyclin A-complex indicates that p27 associates with both
Cdk and cyclin subunits. The binding of p27 to Cdk2-cyclin A-complexes seems to be a two-step
event, where p27 first binds with cyclin followed by Cdk binding (Russo et al., 1996b). Similarly,
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biochemical studies of p27 complexes suggest that p27/p21-cyclin complexes are formed more
readily than p27/p21-Cdk-complexes (Hall et al., 1995). The association of p27 to Cdk2-cyclin A-
complex causes conformational changes in the catalytic cleft of Cdk2 that inactivate the kinase by
hindering of ATP binding and blocking of the CAK phosphorylation site (Russo et al., 1996b). p27
and p21 have been shown to block the phosphorylation of Cdk4 and Cdk2 (Kato et al., 1994;
Aprelikova et al., 1995), although there is also evidence that p27 is unable to block Cdk4
phosphorylation by CAK (Blain et al., 1997). Recent studies also indicate that p27 serves as a
substrate to Cdk2-cyclin E, suggesting that p27 exists also in a complex with Cdk2-cyclin E, which
have been activated by CAK (Morisaki et al., 1997; Müller et al., 1997; Sheaff et al., 1997; Vlach
et al., 1997). Alternatively, the phosphorylation of p27 could be accomplished by intercomplex
instead of intracomplex kinase activity, so that another p27-free Cdk-cyclin complex can phosphorylate
p27 (Montagnoli et al., 1999). In accordance to the structural data, studies by Hengst et al. (1998)
indicate that one molecule of p21 (or p27) bound to Cdk2-cyclin A complex is enough to inhibit the
kinase activity.
In contrast to cyclin E- and A-complexes, studies indicate that p21 and p27 are required for the
activity of cyclin D-complexes. In exponentially growing cells p27 is found predominantly to
associate with Cdk4/6-cyclin D-complexes (Poon et al., 1995; Soos et al., 1996) and p21 is found
as a quaternary complex with Cdk, cyclin and PCNA (Xiong et al., 1992; Zhang et al., 1993; 1994;
Harper et al., 1995). In addition, p27 and p21 antibodies immunoprecipitate kinase activity towards
pRb that can be attributed to Cdk4 and Cdk6 bound to p27 or p21 (Soos et al., 1996; Hauser et al.,
1997; Blain et al., 1997; LaBaer et al., 1997; Dong et al., 1998). It has also been shown that low
concentrations of p21, but not p27 or p57, promote the Cdk4-associated kinase activity, whereas
higher p21 concentrations are inhibitory to Cdk4-complexes (LaBaer et al., 1997). In fact, it has been
shown that p21, p27 and p57 promote the assembly of Cdk4-cyclin D complexes and the proper
function Cdk4-cyclin D-complexes requires p21 and p27 (LaBaer et al., 1997; Cheng et al., 1999;
reviewed by Sherr and Roberts, 1999). Primary mouse fibroblasts lacking genes for both p21 and p27
fail to assemble functional Cdk4-cyclin D-complexes, express cyclin D protein at decreased levels,
and cannot efficiently direct cyclin D into cell nucleus (Cheng et al., 1999). Taken together the data
suggest that p21 and p27 are strong inhibitors of Cdk2, whereas the normal activity of Cdk4/6-
complexes requires p21 and p27 and is not inactivated by p21 or p27.
The difference of inhibitory activity of p21 family members towards cyclin D- and E/A-
complexes is probably due to structural difference of the complex between the Cdk, cyclin and Cdki
subunits. Cdk2 and Cdk4 share only a limited sequence homology. The Cdk-inhibitory domain of
p21, when not associated with Cdks, lacks fixed secondary or tertiary structure as revealed by
spectroscopic studies (Kriwacki et al., 1996). However, when bound to Cdk2 the domain has a
defined structure. The flexibility of the inhibitory domain that is conserved throughout the p21 family
could explain the differency in the ability of p21 family members to inhibit or promote the activity
of different Cdks.
p27Kip1
p27 was originally identified as a Cdk2 and Cdc2 inhibitory molecule present in TGF-β and
contact arrested mink lung and human mammary epithelial cells (Polyak et al., 1994a; Slingerland
et al., 1994) and in lovastatin arrested HeLa cells (Hengst et al., 1994). p27 cDNA was cloned by
two different groups by using TGF-β growth arrested Mv1Lu mink lung epithelial cells (Polyak et
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al., 1994b) and by yeast two- hybrid screen using cyclin D1-Cdk4 as a bait (Toyoshima and Hunter,
1994).
p27 is required in G1/G0-cells to prevent Cdk-activity. Overexpression of p27 leads to G1 arrest
(Toyoshima and Hunter, 1994), and antisense expression of p27 prevents mitogen deprived cells
from arresting in G1 (Coats et al., 1996; Rivard et al., 1996). p27 levels were also found to accumulate
in G1 and decline in S-phase in several human cell lines suggesting a G1/S-phase periodic regulation
(Hengst and Reed, 1996; Millard et al., 1997). High levels of p27 protein are detected in quiescent
and differentiating cells, whereas its levels are decreased in exponentially growing cells (Nourse et
al., 1994; Toyoshima and Hunter, 1994; Kato et al., 1994; Agrawal et al., 1995; Polyak et al., 1994a
and b; Coats et al., 1996; Hengst and Reed, 1996; Millard et al., 1997). Similarly, the half-life of p27
is increased in growth arrested cells (Pagano et al., 1995; Hengst and Reed, 1996). The regulation
of p27 levels is mostly post-transcriptional. p27 mRNA is not regulated in a cell cycle dependent
manner or by growth inhibitory treatments (Polyak et al., 1994b; Toyoshima and Hunter, 1994).
Instead, p27 protein levels are upregulated in G0-arrested HL-60 human promyelotic cells by
increased association of p27 mRNA with polyribosomes (Millard et al., 1997). In addition, the p27
protein levels are regulated by ubiquitin-dependent and -independent proteasome degradation
pathways (Pagano et al., 1995; Montagnoli et al., 1999; Nguyen et al., 1999; Shirane et al., 1999).
The degradation of p27 is cell cycle dependent being maximal in S-phase cells, and low in G1-phase
cells. Degradation of p27 via the ubiquitin pathway is regulated by phosphorylation on thr-187, and
at least Cdk2-cyclin E/A-complexes phosphorylate p27 on this residue in proliferating cells (Sheaff
et al., 1997; Vlach et al., 1997; Montagnoli et al., 1999; Nguyen et al., 1999). Coexpression of p27
with Jab1 protein in mouse fibroblasts enhances p27 degradation. Jab1, which was originally
identified as a co-activator of Jun, accelerates p27 degradation either by moving p27 from the nucleus
into the cytoplasm, or by facilitating p27 phosphorylation at thr-187 (Tomoda et al., 1999).
p27 in cellular differentiation and tumorigenesis
Studies of p27 nullizygous mice show that p27 is not required for normal embryonic development,
but is necessary for normal growth control. The p27-/- mice develop to term normally, but attain an
increased body size within three to six weeks after birth (Fero et al., 1996; Kiyokawa et al., 1996;
Nakayama et al., 1996). In addition, the females are infertile due to inability of ovarian follicles to
form corpora lutea (Fero et el., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996). The increased
body size is due to increased number of cells in every tissue suggesting that the absence of p27 allows
continued cell proliferation (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996).
However, terminal differentiation of organs from p27 nullizygous mice is normal indicating that p27
is not essential for differentiation but it is needed for regulation of withdrawal from the mitotic cycle
(Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996). In concordance, interleukin-2 has
been shown to downregulate p27 protein levels leading to Cdk2-activation and T-cell proliferation
(Nourse et al., 1994), and p27 is required for cell cycle withdrawal in the oligodendrocyte lineage
(Casaccia-Bonnefil et al., 1997).
The ability of p27 to inhibit cyclin-Cdk-activity and to induce G1 arrest when overexpressed
suggests that it is a tumor suppressor candidate. Abnormally low p27 protein levels in human tumors
correlate directly with both histological aggressiveness and patient mortality (Esposito et al., 1997;
Loda et al., 1997; Porter et al., 1997; Yang et al., 1997). However, no human tumors that have lost
the both alleles of the p27 gene have been found. Therefore p27 is not a tumor suppressor complying
Knudson two-hit-theory (Knudson, 1971). Mice nullizygous for p27 exhibit pituitary hyperplasia
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and adenomas that showed no sign of invasion or metastasis in mice up to 7 months of age (Fero et
al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996). On the other hand, mice nullizygous or
heterozygous for p27 are predisposed to tumors when treated with ionizing radiation or chemical
carcinogens suggesting that p27 is indeed a tumor suppressor in mice (Fero et al., 1998). Molecular
analysis of the remaining allele from tumors of p27 heterozygous mice revealed that the allele was
intact suggesting that p27 is a haplo-insufficient tumor suppressor (Fero et al., 1998).
p21 CIP1,WAF1,Sdi1 and p57Kip2
p21 was cloned by several groups using different approaches. Initially it was purified from cellular
lysates as an inhibitor of Cdk-activity (Gu et al., 1993; Xiong et al., 1993a). p21 was cloned as a
mRNA upregulated by p53 (Waf1; El-Deiry et al., 1993) and cellular senescence (Sdi1; Noda et al.,
1994), and also identified by yeast two-hybrid screen as a protein binding to Cdk2 and inhibiting its
activity (Cip1; Harper et al., 1993). Finally, a p53-induced Cdk-inhibitor was found in gamma-
irradiated cells and identified as p21 (Dulic et al., 1994). The approaches by which p21 was identified
reflect its function as a Cdk inhibitor that is induced by p53 and cellular senescence.
The role of p21 as a mediator of p53 growth arrest in G1 after DNA damage is well documented.
p53 induces p21 at mRNA level after DNA damage caused by UV- or ionizing radiation or chemicals,
such as adriamycin (Dulic et al., 1994; reviewed by El-Deiry, 1998). p21-nullizygous fibroblasts are
impaired in their ability to arrest in G1 as response to DNA damage or depletion of nucleotide pools.
However, the p53-mediated apoptosis is normal in p21-/- cells suggesting that p21 is needed for p53
mediated G1 checkpoint but not for apoptosis (Brugarolas et al., 1995; Deng et al., 1995; Macleod
et al., 1995). Similarly, a p21-deficient human adenocarcinoma cell line lacks G1 arrest in response
to DNA damage and p53 induction (Waldman et al., 1995). On the other hand, p21 has a p53-
independent role in development and differentiation of some cell types. p21 expression in various
tissues during development and in the adult mouse is p53-independent (Macleod et al., 1995), and
the expression pattern of mouse p21 correlates with terminal differentiation (Parker et al., 1995).
p57 was isolated by using p21 as a probe to screen mouse cDNA library (Lee et al., 1995) and also
found in a yeast two-hybrid screen using cyclin D1 as a bait (Matsuoka et al., 1995). Like other p21
family members, overexpression of p57 leads to G1 arrest (Lee et al., 1995; Matsuoka et al., 1995).
The mRNA expression pattern of p57 is tissue specific, and most of the cells expressing p57 are
terminally differentiated (Lee et al., 1995; Matsuoka et al., 1995). Interestingly, p57 is subject to
imprinting with preferential expression of the maternal allele both in humans and mice (Hatada and
Mukai, 1995; Matsuoka et al., 1996). The human p57 gene is located in the 11p15.5 region that is
implicated in sporadic cancers and Beckwith-Wiedeman cancer syndrome (Matsuoka et al., 1995).
However, p57 nullizygous mice do not develop neoplasia (Yan et al., 1997), although the phenotype
of p57-/- mice resembles that of Beckwith-Wiedeman syndrome patients (Zhang et al., 1997a). p57-
/- mice have severe defects in cellular proliferation and differentiation and most of them die soon after
birth (Zhang et al., 1997a; Yan et al., 1997).
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p16 family
Structural motifs of the p16 family
The p16 family contains of four closely related members, which all inhibit the activity of Cdk4
and Cdk6. The members of p16 family are p16INK4A,MTS1 (Serrano et al., 1993), p15INK4B,MTS2 (Hannon
and Beach 1994), p18INK4C and p19INK4D (Guan et al., 1994; Hirai et al., 1995; Chan et al., 1995). p15
and p16 contain four ankyrin repeats, whereas p18 and p19 have five (Serrano et al., 1993; Hannon
and Beach, 1994; Guan et al., 1994; Chan et al., 1995; Hirai et al., 1995; Russo et al., 1998). The
ankyrin repeats mediate protein-protein interactions (reviewed by Sedgwick and Smerdon, 1999),
and are formed of helix-turn-helix structures (Tevelev et al., 1996). p16 family members associate
with Cdk4 or 6 at 1:1 stoichiometry and are found both in vivo and in vitro in Cdk4 or 6 complexes
devoid of D-type cyclins resulting in loss of  the kinase activity (Serrano et al., 1993; Guan et al.,
1994, 1996; Hall et al., 1995; Parry et al., 1995; Ragione et al., 1996). In addition, p16 can replace
cyclin D from Cdk4 complexes in vitro (Ragione et al., 1996). A peptide of 20 amino acids from the
third ankyrin repeat area of p16 has been shown to be able to bind to Cdk4 and 6 in vitro (Fåhraeus
et al., 1996).
In vitro studies and solution structure of p16 suggest that the binding sites for cyclin D1 and p16
in Cdk4 are overlapping and located primarily near the amino-terminus of Cdk4 (Coleman et al.,
1997; Byeon et al., 1998). Structural studies of the p16-Cdk6 and p19-Cdk6 complexes suggest that
association with p16 family members prevents ATP binding of Cdk6, and that p16 indirectly
prevents Cdk6 from binding to cyclin D (Brotherton et al., 1998; Russo et al., 1998). The structural
studies also suggest that p16 loss-of-function mutations found in cancer cells result in incorrectly
folded or insoluble protein (Zhang and Peng, 1996; Luh et al., 1997; Brotherton et al., 1998; Byeon
et al., 1998).
 p16INK4A,MTS1 acts in pRb pathway
p16 was originally cloned in a yeast two-hybrid screen using Cdk4 as a bait, thus the name INK4,
inhibitor of Cdk4 (Serrano et al., 1993). In addition, p16 was cloned as a gene associated with a
chromosome 9p21 locus mutated in melanomas and named MTS1 (multiple tumor suppressor-1;
Kamb et al., 1994; Nobori et al., 1994).
p16 acts on the same pathway as pRb. Overexpression of p16 leads to G1 arrest in various cell lines
and suppresses cellular transformation (Guan et al., 1994; Jin et al., 1995; Lukas et al., 1995c;
Medema et al., 1995; Serrano et al., 1995; Fueyo et al., 1996), whereas overexpression of p16 in cells
lacking functional pRb did not arrest cells in G1 (Guan et al., 1994; Lukas et al., 1995c; Medema et
al., 1995). Interestingly, p16 levels are elevated in cell lines lacking functional pRb (Serrano et al.,
1993; Xiong et al., 1993b; Otterson et al., 1994; Parry et al., 1995; Tam et al., 1994b). In SV40,
adeno- or papillomavirus transformed cells Cdk4 is associated predominantly with p16 (Serrano et
al., 1993; Xiong, et al., 1993b), whereas in normal human fibroblasts Cdk4 is in quaternary complex
with cyclin D, p21 and PCNA (Xiong et al., 1992, 1993a; Zhang et al., 1993). These results suggest
that pRb would function as a sole target of cyclin D-associated kinase in G1, and in cells lacking pRb
cyclin D-associated kinase would not be necessary for cell proliferation. In accordance, prevention
of cyclin D expression in cells lacking functional pRb, unlike in their normal counterparts, did not
lead in G1 arrest (Tam et al., 1994a; Lukas et al., 1995b). In addition, p16 suppresses neoplastic
transformation of cultured fibroblasts by oncogenic Ha-Ras and c-Myc but not by Ha-ras and E1A,
further verifying that p16 lies in pRb pathway (Serrano et al., 1995).
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The high levels of p16 in cells lacking functional pRb suggested a feedback loop where pRb would
regulate the amount of p16 (Serrano et al., 1993; Xiong et al., 1993b; Otterson et al., 1994; Tam et
al., 1994b; Parry et al., 1995). However, the p16 levels are not regulated in a cell cycle specific
manner. Instead, p16 expression is tissue specific and p16 accumulates in late-passage, senescent
cells (Hara et al., 1996; Jen et al., 1994; Zindy et al., 1997). Similarly, premature senescence of
primary human or rodent fibroblasts induced by oncogenic Ras is accompanied by accumulation of
p16 and p53 (Serrano et al., 1997), whereas immortalization of human cell lines is facilitated by
inactivation of p16 and/or p53 tumor suppressor (Reznikoff et al., 1996).
p15INK4B, MTS2 is regulated by TGF-β
p15 was cloned from a cDNA library of TGF-β treated HaCaT human keratinocytes using p16
as a probe (Hannon and Beach, 1994) and from a HeLa cDNA library (Guan et al., 1994).
Additionally, Kamb et al. (1994) had noted p15 sequence in close proximity of p16 in human
chromosome 9 during their effort of cloning a melanoma-linked gene, which turned out to be p16.
p16 and p15 are close homologues of each other, especially in the exon two area (97% identity at the
amino acid level; Hannon and Beach, 1994). The close linkage and strong homology between p16
and p15 suggest that they arose from a duplication of a single ancestral gene (Fig. 3; Jiang et al.,
1995).
p15 expression, like that of p16, is low in mouse embryos (Zindy et al., 1997). However, in
contrast to p16 which has a restricted expression pattern, p15 expression can be detected in several
organs of adult mice and humans, such as kidney, lung and testis (Jen et al., 1995; Stone et al., 1995a;
Zindy et al.,1997). The mRNA expression of p15 is not regulated in a cell cycle specific manner,
neither are p15 mRNA levels elevated in cells lacking functional pRb (Stone et al., 1995a). Instead,
in TGF-β growth arrested human keratinocytes, mink lung and mammary epithelial cells p15 mRNA
and protein are rapidly induced. The increased p15 levels associate with Cdk4 and 6 and inhibit their
activity (Hannon and Beach, 1994; Reynisdóttir et al., 1995; Sandhu et al., 1997). A consensus Sp-
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Fig. 3 The genomic organization of p15, p16 and p14ARF in human chromosome 9p21. The exons are
marked as boxes, the splicing with dotted lines, and the transcription start sites with arrowheads. The
protein products of p15, p16 and p14ARF are shown below. In addition, the alternatively spliced form
of p15, p10, together with its in vitro translation product is  shown (see Results & Discussion for
details). The protein products and the locus are not drawn in scale. Studies indicate that the locus
spans more than 30 kb, and the exon 1β of p16/p14ARF lies in close proximity (2.3 kb) to exon 2 of
p15 and over 20 kb from 1α of p16. The intron 1 area of p15 as well as intron 1 and 2 of p14ARF are
approximately 2.5 kb in length (Mao et al., 1995; Stone et al., 1995b; adapted from Haber, 1997).
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1 transcription factor binding site has been shown to facilitate the TGF-β induction of p15 mRNA
(Li et al., 1995a). In addition, interferon-α (IFN-α) has been shown to induce p15 mRNA and protein
levels in a hematopoietic cell line that is growth arrested by IFN-α (Sangfelt et al., 1997).
p16 and p15 loci  as tumor suppressors
It is suggested that p16 and 15 are tumor suppressor proteins. They both inactivate the Cdk4/6
kinases (Serrano et al., 1993; Hannon and Beach, 1994), and their overexpression prevents cellular
growth (Guan et al., 1994; Jin et al., 1995; Medema et al., 1995; Lukas et al., 1995c; Serrano et al.,
1995; Stone et al., 1995a; Fueyo et al., 1996). They were also cloned from an area linked to putative
melanoma tumor suppressor (Kamb et al., 1994). p16 was initially named as the multiple tumor
suppressor located in human chromosome 9p21 (Kamb et al., 1994; Nobori et al., 1994). The coding
sequence for p15 was not found to be altered in tumor cell lines examined in contrast to p16 sequence,
and therefore p15 was first thought to be a pseudogene (Kamb et al., 1994). The p16 gene is altered
in high percentage of cells in many human tumors including melanomas, gliomas, lung cancer and
leukemias. It is inactivated by several different mechanisms including homozygous deletion, point
mutation, and silencing by CpG methylation (reviewed by Kamb, 1998). However, p16 germline
mutations are rare in contrast to common p16 somatic mutations (Kamb, 1998). Loss of p15 is also
common in many transformed cell lines. However, only a couple mutations in p15 have been detected
from tumors with normal p16 status. Certain primary non-small cell lung carcinomas were found to
have three intragenic mutations of p15 (Okamoto et al., 1995) and an esophagus carcinoma one
missense mutation (Suzuki et al., 1995). In contrast, screens of melanoma-prone kindred with intact
p16 did not reveal any p15 mutations (Stone et al., 1995a; reviewed by Kamb, 1998). The data
suggest that the p16 locus contains the tumor suppressor, and the loss of the p16 locus is most
probably the primary target, whereas loss of p15 occurs simply because of its close proximity to p16.
However, loss of p15, in addition to loss of p16, could give a growth advantage to cancerous cells.
The phenotype of p16 knock-out mice further indicated a tumor suppressor role for the INK4A
locus. These mice develop normally suggesting that p16 is a non-essential gene for viability and
proper development (Serrano et al., 1996). However, they develop spontaneous tumors at an early
age, most of the tumors being soft tissue sarcomas and B-cell lymphomas. The incidence of tumors
is accelerated by irradiation or by treatment with chemical carcinogens (Serrano et al., 1996). In
addition, the p16-null mouse embryo fibroblasts do not undergo replicative senescence in culture.
In contrast to normal mouse embryo fibroblasts, they can be transformed oncogenic by Ras without
a co-operating oncogene such as myc or adenovirus E1A (Serrano et al., 1996).
p16 has an alternatively spliced form called p14ARF in humans or p19ARF in mouse (Alternative
Reading Frame) that utilizes the p16 exon 2, but has a novel first exon called 1β . The p16 and p14/
19ARFgenes are transcribed in different reading frames, and thus the product p14/19ARF has no
homology to the p16 Cdki family (Fig. 3; Duro et al., 1995; Mao et al., 1995; Quelle et al., 1995;
Stone et al., 1995b). Accordingly p14/19ARF does not bind Cdks, but its overexpression arrests cells
in G1 and G2 (Quelle et al., 1995). p14/19ARF has been shown to be involved in regulation of p53 tumor
suppressor by binding to Mdm-2 and preventing Mdm-2 induced p53 degradation (reviewed by
Sherr, 1998).
The results from p16-/- mice were complicated after the finding that the targeted disruption of
p19ARFexon 1β generated a similar phenotype as that of the p16-null mice, where the common exons
2 and 3 were disrupted (Kamijo et al., 1997). Most importantly, the expression of p16 protein was
intact in p19ARF-knockout tissues, cultured cells and tumors derived form the mice, suggesting that
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A 3. Transforming growth factor-β
Transforming growth factor-β (TGF-β) belongs to a large family of growth factors named TGF-
β superfamily that regulates cellular growth and differentiation (reviewed by Massagué, 1996, 1998;
Taipale et al., 1998). TGF-β inhibits the growth of epithelial, endothelial and hematopoietic cells,
stimulates extracellular matrix formation and is an immunosuppressor. TGF-β treatment arrests
epithelial and endothelial cells in the G1-phase of the cell cycle. TGF-β is a 25-kDa homodimeric
growth factor, and three isoforms are found in mammals, namely TGF-β:s 1 to 3. Also heteromeric
active complexes, such as TGF-β1.2 and 2.3 have been found in vivo (Cheifetz et al., 1987; Ogawa
et al., 1992). Originally, TGF-β1 was identified as a sarcoma growth factor (SGF) together with
TGF-α (transforming growth factor-α) and purified from murine sarcoma virus transformed
fibroblasts (DeLarco and Todaro, 1978). SGF stimulated cellular growth and colony formation in
soft agar, and was later found to consist of two different growth factors named TGF-α and -β (Anzano
et al., 1982, 1983).
p19ARFis the tumor suppressor gene, and the phenotype observed earlier in the p16-/- animals is due
to p19ARFinactivation and not to that of p16. However, the final effect of p16 on the phenotype remains
uncertain since currently there are no true p16 knockout mice with normal p19ARF expression.
On the other hand, analysis of the p16 protein structure suggests that p16 is indeed a tumor
suppressor. A number of p16 point mutations found in cancers prevent p16 binding to Cdk4/6,
because they encode a protein that is incorrectly folded or insoluble (Koh et al., 1995; Zhang and
Peng, 1996; Luh et al., 1997; Byeon et al., 1998; Russo et al., 1998). In addition, a Cdk4 mutant found
in melanomas has a greatly reduced ability to bind p16 (Wolfel et al., 1995). So far no definite
germline mutations have been described from melanoma patients that would selectively destroy
p14ARF exon 1β and leave the common exon 2 intact. In contrast, some mutations are specifically
targeted towards exon 1α of p16 indicating that p16 is a tumor suppressor (FitzGerald et al., 1996).
 p18INK4C and p19INK4D
p18 and p19 genes were isolated in a yeast two-hybrid screen using Cdk4 and Cdk6 as baits (Hirai
et al., 1995; Guan et al., 1994). p19 was also cloned through its interaction in yeast with Nur 77
orphan steroid receptor that shows no link to cell cycle regulation (Chan et al., 1995). Mouse p18 and
p19 share approximately 40% identity at protein level (Hirai et al., 1995).
Overexpression of p19 causes growth arrest regardless of the pRb status of the cells, whereas p18,
similar to p16, can only arrest cells that have functional pRb (Guan et al., 1994; Hirai et al., 1995).
No mutations of p18 or p19 have been found in cell lines or in primary tumors (reviewed by Carnero
and Hannon, 1998). The function of p18 is suggested to regulate senescence and terminal
differentiation:. p18 levels increase during senescence of mouse embryonic fibroblasts and myogenic
differentiation (Franklin and Xiong, 1996; Zindy et al., 1997). Interestingly, the phenotype of mice
lacking p18 is similar to that of p27-/- animals. The p18-/- mice have increased body size due to
organomegaly, and they develop pituitary hyperplasia and adenomas. Mice lacking both p18 and p27
develop pituitary adenomas faster than mice lacking either of the Cdkis, and at a similar rate as mice
chimerical for pRb deficiency suggesting functional collaboration of these two Cdk inhibitors in the
pRb pathway (Franklin et al., 1998).
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Fig. 4 The TGF-β intracellular
signaling pathway. Ligand
binding to TGF-β receptor
type II induces hetero-
oligomerization of the
receptor complex and
subsequent phosphorylation
of receptor type I. The
phosphorylated receptor type
I then phosphorylates Smad2
and 3 resulting in their
association with Smad4 and
translocation into the nucleus
where they activate transcrip-
tion of target genes. Smad6
and 7 can inhibit the Smad2
and 3 phosphorylation by pre-
venting their access to
receptor type I (modified from
Heldin et al., 1997; Massagué
et al., 1998).
TGF-β signal transduction
The TGF-β signaling is initiated by ligand binding to transmembrane heteromeric kinase complex
consisting of two serine-threonine kinases. TGF-β and its signaling receptors I and II are expressed
in mesenchymal and epithelial cells (reviewed by Taipale et al., 1998). Both receptors I and II are
needed for signal transduction (Fig. 4; Franzen et al., 1993; Ventura et al., 1994; Wrana et al., 1994).
The type II receptor binds to the ligand (Wrana et al., 1992), whereas the type I receptor is required
for downstream signaling (Carcamo et al., 1994; ten Dijke et al., 1994). Phosphorylation of the type
I receptor by type II receptor, after ligand binding, initiates the downstream signaling (Wrana et al.,
1994). In addition, TGF-β binds to accessory receptors called betaglycan and endoglin (Gougos and
Letarte 1990; Wang et al., 1991; Lõpez-Casillas et al., 1994; Yamashita et al., 1994). They have been
suggested to regulate the access of TGF-β to the signaling receptors.
Loss of TGF-β receptors could give a growth advantage to certain preneoplastic cells. Loss of one
or more TGF-β signaling receptors occurs in certain tumors such as neuro- and retinoblastomas,
prostate carcinoma and in several leukemia cell lines (Kimchi et al., 1988; Keller et al., 1989; Kim
et al., 1996a). There is also evidence of specific frameshift or point mutations associated with TGF-
β receptors I and II in colon carcinoma and prostate cancers cells (Markowitz et al., 1995; Kim et
al., 1996b).
TGF-β intracellular signaling is at least partly mediated by Smad proteins (Fig. 4; reviewed by
Massagué, 1996; Heldin et al., 1997). The activated type I receptor phosphorylates Smad2 and
Smad3, which form a heteromeric complex with a common mediator Smad4 (Zhang et al., 1996,
1997b; Eppert et al., 1996; Lagna et al., 1996; Macias-Silva et al., 1996; Nakao et al., 1997a; Wu
et al., 1997). The complex is then translocated to the nucleus where it regulates transcription of target
genes (Chen et al., 1996c; Macias-Silva et al., 1996; Eppert et al., 1996; Liu et al., 1997a, b; Nakao
et al., 1997a; Dennler et al., 1998). Smad4 is also called DPC4 (deleted in pancreatic carcinoma,
locus 4), a tumor suppressor gene mutated or deleted in breast, lung, head, neck and ovarian cancers,
as well as pancreatic malignancies (Hahn et al., 1996; Massagué 1998).
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Other Smads, namely Smad6 and 7 may participate in a negative feedback loop to control
intracellular signaling. TGF-β rapidly induces expression of Smad7 mRNA (Nakao et al., 1997b).
Smad6 and 7 associate with the type I receptor but are not phosphorylated. The association blocks
the access and activating phosphorylation of Smad2 and 3, and thus prevents signal transduction
(Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997b).
TGF-β as a growth inducer
The effects of TGF-β on cell proliferation are dependent on cell type, state of differentiation, and
presence of other growth factors (reviewed by Ravitz and Wenner, 1997). Although TGF-β1 was
originally identified as part of a growth promoting factor (DeLarco and Todaro, 1978), it is a potent
inhibitor of epithelial, endothelial and lymphoid cell growth (Tucker et al., 1984; Shipley et al., 1986;
Silberstein and Daniel 1987; Russell et al., 1988). However, it can stimulate the growth of
mesenchymal cells, particularly rodent and human fibroblasts (Shipley et al., 1985; Soma and
Grotendorst, 1989).
The stimulatory effect of TGF-β on mesenchymal cell growth seems to depend on the cell culture
conditions, cell density, TGF-β concentration and presence of other growth factors (Battegay et al.,
1990; Roberts et al., 1985; Goodman and Majack, 1989). For instance, TGF-β together with PDGF
(platelet derived growth factor) stimulates the colony formation of Fischer rat 3T3 transfected with
c-myc, whereas it inhibits the growth and antagonizes the effect of epidermal growth factor (EGF)
on colony formation of the same cells (Roberts et al., 1985). In addition, primary and secondary
rodent fibroblasts are growth arrested in G1 by TGF-β, whereas immortalized cell lines derived from
these cells are not (Sorrentino and Bandyopadhyay, 1989). Similarly, TGF-β stimulates growth of
Ha-Ras transformed metastatic fibroblasts, whereas it inhibits the growth of the non-transformed
parental cell line (Schwarz et al., 1988).
TGF-β induced DNA synthesis of mesenchymal cells occurs with slower kinetics than the EGF,
PDGF or serum induced synthesis (Shipley et al., 1985; Soma and Grotendorst, 1989; Kim et al.,
1993). The growth stimulatory effect of TGF-β is suggested to be indirect, and mediated by autocrine
induction and secretion of PDGF (Mäkelä et al., 1987; Soma and Grotendorst, 1989; Battegay et al.,
1990).
Growth inhibitory effects of TGF-β mediated by cell cycle machinery proteins
pRb as a mediator of TGF-β growth inhibitory signal
The TGF-β induced G1 growth arrest is reversible, and occurs only if TGF-β is added to cell
culture prior to the restriction (R) point in G1 (Laiho et al., 1990; Howe et al., 1991). TGF-β treatment
of Mv1Lu cells prevents the phosphorylation of pRb, which normally occurs late in G1 approximately
during the time of the restriction point (Laiho et al., 1990). When TGF-β is added after the R point,
pRb phosphorylation is not prevented, and the cells proceed into S. In addition, expression of SV40
large T antigen in Mv1Lu cells prevents the TGF-β growth arrest without blocking the phosphorylation
of pRb (Laiho et al., 1990). SV40 large T binds specifically to underphosphorylated pRb and
prevents its function (DeCaprio et al., 1988). p107 and p130, members of the pRb family, have also
been found to be involved in the TGF-β growth arrest pathway. In 32D-123 murine myeloid cells
TGF-β treatment prevents p107 phosphorylation, and expression of p107 antisense oligo nucleotides
prevents TGF-β growth arrest (Bang et al., 1996). In HFK human keratinocytes and HaCaT human
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keratinocyte cells TGF-β inhibits the E2F activity by increasing the amount of E2F associated with
p130 (Herzinger et al., 1995). In addition, infection of Mv1Lu cells with an adenovirus expressing
the pRb target E2F-1 prevents TGF-β growth inhibition (Schwarz et al., 1995). Taken together, these
data suggest that pRb (and its family members) are needed for TGF-β growth arrest and, in addition,
that TGF-β has an inhibitory effect on the cyclin dependent kinases that are essential for inactivation
of pRb.
Cdk inhibitors as mediators of TGF-β growth arrest
TGF-β has been shown to have inhibitory effects on Cdk2, 4, and 6 kinase activities. The
mechanisms of TGF-β growth inhibition have been studied in different cell models, and the
mechanisms of Cdk inhibition by TGF-β vary from one cell line to another. The inhibitory
mechanisms include downregulation of the amount of Cdk or cyclin subunit, as well as regulation
of Cdk phosphorylation status and association with Cdki proteins (Fig. 5 and Table 2).
The Cdk inhibitors p15, p27 and p21 have been found to be involved in TGF-β induced growth
arrest, and suggested to be the major mediators of Cdk inhibition by TGF-β. There are cell type
specific differences in which Cdkis are induced to accumulate into Cdk-complexes after TGF-β
treatment. The Cdkis may have overlapping functions and they may compensate for one another.
Alternatively, other mechanisms to inactivate Cdk-cyclin complexes could replace the lack of a
certain Cdki in a specific cell type (Table 2). Indeed, TGF-β can still arrest growth of cells lacking
either p15 or p27 (Nakayma et al., 1996; Iavarone and Massagué, 1997).
Co-operation between p15 and p27 in TGF-β growth arrest
The best known model for TGF-β growth inhibition involves accumulation of p15 and p27 to
Cdk4/6- and Cdk2-complexes, respectively. p15 and p27 seem to co-operate at least in HaCaT
keratinocytes, Mv1Lu mink lung epithelial and HMEC 184 human mammary epithelial cells to
mediate TGF-β growth arrest (Reynisdóttir et al., 1995; Reynisdóttir and Massagué, 1997; Sandhu
et al., 1997). TGF-β induces p15 mRNA. The induction is observed after two hours in HaCaT and
Mv1Lu cells (Hannon and Beach, 1994; Reynisdóttir et al., 1995) followed by accumulation of p15
to Cdk6 and Cdk4 complexes (Hannon and Beach, 1994; Reynisdóttir et al., 1995; Sandhu et al.,
1997). The accumulation of p15 to Cdk4 and Cdk6 complexes displaces p27 Cdki from these
complexes leading to inactive Cdk4 or 6 bound to p15 (Reynisdóttir et al., 1995; Reynisdóttir and
Massagué, 1997; Sandhu et al., 1997). TGF-β treatment does not affect the mRNA or protein levels
of p27 (Polyak et al., 1994b; Sandhu et al., 1997). Instead, p27 is redistributed into Cdk2-cyclin E-
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CYCLIN D
P-tyr
CDK2
CYCLIN E
p21
CDK2
CYCLIN E
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CDK4/6
CYCLIN D p27
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CYCLIN E
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Fig. 5 Inhibitory effects of TGF-β
on the activity of Cdk-complexes.
TGF-β treatment induces
upregulation of p15 and p21 Cdk
inhibitors, and their association with
Cdk4/6 and Cdk2 complexes, re-
spectively. In addition, upregulation
of p15 replaces p27 in Cdk4/6 com-
plexes leading to the association of
p27 with Cdk2 complexes and their
inactivation. TGF-β prevents also
tyr-dephosphorylation of Cdk4/6 by
downregulating the Cdc25A
phosphatase, and the thr-
phosphorylation of Cdk2 (see text
for details and references).
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complexes, resulting in inhibition of Cdk2 activity (Reynisdóttiret al., 1995; Reynisdóttir and
Massagué, 1997; Sandhu et al., 1997).
The different subcellular localizations of p15 and p27 have been suggested to be important for the
ability of p15 and p27 to bind to and inhibit different Cdk-cyclin complexes. p15 cannot displace p27
from Cdk4 complexes unless it has access to them prior to p27 in vitro (Reynisdóttir and Massagué,
1997). p15 is predominantly cytoplasmic, whereas p27 is nuclear. According to the model by
Reynisdóttir and Massagué (1997), the nuclear Cdk4-cyclin D-p27-complexes turn over rapidly
since the short half-life of cyclin D (30 min; Matsushime et al., 1991). After dissociation from cyclin
D, Cdk4 is returned to cytoplasm where it can bind to p15. Once p15 is associated with Cdk4, Cdk4
can no longer associate with cyclin, and p27 can no longer displace p15 leading to accumulation of
free p27. p27 is then able to associate with and inhibit the activity of Cdk2-complexes (Reynisdóttir
et al., 1995; Reynisdóttir and Massagué, 1997; Sandhu et al., 1997). In addition, the different binding
mechanisms and affinities towards Cdk and cyclin subunits of p15 and p27 support this model.
Structural studies indicate that p16 family members bind only to the Cdk-subunit, and that binding
of p16 can prevent cyclin D association to Cdk6 (Russo et al., 1998). Structural studies of Cdk2-
cyclin A-p27 complex suggest that p27 needs cyclin as a docking site for Cdk binding (Russo et al.,
1996b).
p15 mRNA induction by TGF-β is also observed in a derivate of HMEC 184 cell line, 184A1L5
that is not growth arrested by TGF-β (Sandhu et al., 1997), and in several squamous carcinoma cell
lines, some of which are growth inhibited by TGF-β while others are not (Table 2; Malliri et al.,
1996). One possible mechanism explaining the lack of TGF-β growth arrest in 184A1L5 cells after
p15 mRNA induction is a difference in p15 half-life. In the TGF-β sensitive HMEC 184 mammary
epithelial cells the half-life of p15 protein is increased by TGF-β treatment, whereas TGF-β
treatment had no effect on the half-life of p15 from the 184A1L5 cells (Sandhu et al., 1997). In
addition, the authors found that p15 from the TGF-β resistant 184A1L5 cell line was unable to
displace cyclin D1 from Cdk4 complexes in contrast to p15 present in the sensitive cell line,
suggesting that TGF-β treatment is able to modify either p15 or Cdk4-cyclin D-complexes by some
unknown mechanism(s). Subsequently, there was no accumulation of p27 to Cdk2-cyclin E-
complexes (Sandhu et al., 1997).
p21 mediates TGF-β growth arrest in some cell types
In addition to inducing accumulation of p27 to Cdk2-complexes, TGF-β can inhibit Cdk2 activity
by inducing p21. In contrast to p27, the p21 induction takes place at the mRNA level (Table 2;
Elbendary et al., 1994; Datto et al., 1995; Li et al., 1995b). The induction of p21 mRNA is rapid, and
it can be observed as early as one hour after TGF-β treatment of asynchronously growing HaCaT
cells (Datto et al., 1995), whereas the increased p21 protein levels can be detected after two to four
hours (Reynisdóttir et al., 1995). In HaCaT cells three Cdkis seem to co-operate to induce growth
arrest as response to TGF-β treatment. p15 inactivates Cdk4/6-complexes, whereas the induced p21
associates with and inactivates Cdk2 together with p27 (Reynisdóttir et al., 1995). TGF-β induces
p21 also in several cell lines, such as WM35 melanoma, IEC 4-1 rat intestinal, human squamous
carcinoma and prostate cells, some of which lack p15 induction (Table2; Flørens et al., 1996; Malliri
et al., 1996; Cipriano and Chen, 1998; Yue et al., 1998). At least in some of these cells where p15
induction is not observed, p21 seems to co-operate with p27 to arrest cells after TGF-β treatment
(Flørens et al., 1996; Yue et al., 1998).
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Table 2. Effects of TGF- on G and G /S specific Cdk-cyclin complexes in different cell lines. 1 1
Cell lineSubunit Effect/ Mechanism Reference
Cdk4 downregulation of protein
synthesis
downregulation of protein levels
Mv1Lu
HaCaT
WM35 melanoma
squamous carcinoma
cell lines
Ewen ., 1993
Reynisd ttir ., 1995
et al
ó
ø
et al
et al
et al
Fl rens ., 1996
Malliri ., 1996
Cdk6 downregulation of protein
synthesis
Mv1Lu Reynisd ttir ., 1995,
III
et aló
Cdk2/4/6 inhibition of upregulation of
mRNA after serum stimulation
HaCaT Geng and Weinberg, 1993
cyclin D1 downregulation of protein
downregulation of mRNA
WM melanoma
IEC-6 and RIE-1 rat
intestinal epithelial
Fl rens ., 1996
Ko ., 1995
et al
et al
ø
Cdk2 downregulation of thr-160
phosphorylated form
Mv1Lu Koff ., 1993et al
p15 upregulation of mRNA and
protein
HaCaT
Mv1Lu
HMEC 184
Hannon and Beach, 1994
Reynisd ttir ., 1995
Sandhu ., 1997
et al
et al
ó
p27 upregulation of protein synthesis IEC 4-1 rat intestinal
epithelial
Yue ., 1998et al
p21 upregulation of mRNA and
protein
HaCaT
OVCA 420 ovarian
cancer
LS1034 and LS513
colon cancer
Datto ., 1995
Elbendary ., 1994
Li ., 1995
et al
et al
et al
Cdk4/6 increased tyr-phosphorylation MCF-10A
mammary epithelial
Iavarone and Massague,
1997
Viral oncoproteins prevent TGF-β growth arrest by binding to Cdkis
In addition to direct binding to pRb and its family members (Pietenpol et al., 1990; Missero et al.,
1991), adenovirus E1A oncoprotein can override TGF-β growth arrest by preventing inactivation of
Cdk-complexes by Cdkis. E1A oncoprotein can block the transcriptional induction of p15 and p21
by TGF-β in HaCaT cells (Datto et al., 1997) explaining how E1A can stimulate pRb phosphorylation
in the presence of TGF-β (Wang et al., 1991; Datto et al., 1997). The effect of E1A on p15
transcription is mediated through the ability of E1A to bind p300 transcriptional co-activator (Datto
et al., 1997). E1A can rescue TGF-β growth arrest in Mv1Lu cells by binding to and blocking the
inhibitory effect of p27 thus restoring the Cdk2-associated kinase activity (Mal et al., 1996).
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The effects of TGF-β on Cdk and cyclin subunits
Inactivation of Cdk-complexes by Cdkis is not the sole mechanism by which TGF-β prevents
kinase activity. However, in the most studied cell models the effects of TGF-β on Cdk levels or
phosphorylation status seem to occur in addition to Cdki accumulation. TGF-β treatment has been
shown to decrease the amount of Cdk4 and Cdk6 (Table 2; Ewen et al., 1993b; Reynisdóttir et al.,
1995; Flørens et al., 1996; Malliri et al., 1996). The decrease of the amount of Cdk4/6 protein levels
occurs with slower kinetics than upregulation of Cdki proteins to Cdk complexes. At least in Mv1Lu
cells the effect of TGF-β on Cdk4/6 levels is post-transcriptional since TGF-β has no effect on Cdk4
mRNA levels (Ewen et al., 1993b) but it decreases the amount Cdk4 and Cdk6 synthesis (Ewen et
al., 1993b; Reynisdóttir et al., 1995). However, TGF-β can block growth stimulatory effects of serum
stimulation on synchronized HaCaT human keratinocytes by preventing upregulation of Cdk2, 4,
cyclin E and A mRNA levels (Geng and Weinberg, 1993).
Regulation of the activator thr-phosphorylation seems to be another mechanism of Cdk2
inhibition by TGF-β. TGF-β prevents the accumulation of active Cdk2-cyclin E complexes without
affecting the protein levels of Cdk2 or cyclin E by decreasing the amount of thr-phosphorylated form
of Cdk2 (Koff et al., 1993). The decrease of the amount of thr-phosphorylated Cdk2 is probably due
to increased association of Cdk2 with p27 that blocks the CAK phosphorylation site of Cdk2 (Russo
et al., 1996b). Increased tyrosine-phosphorylation of Cdk4 and 6 is suggested to be an alternative
mechanism of Cdk inhibition when p15 induction is lacking. In MCF-10A mammary epithelial cells
TGF-β has been shown to downregulate Cdc25A phosphatase mRNA and protein levels leading to
accumulation of tyrosine phosphorylated, inactive forms of Cdk4 and 6 (Iavarone and Massagué,
1997). In these cells Cdk2 was similarly phosphorylated in thr-and tyr-residues both in control and
TGF-β treated cells. In HaCaT cells, Cdc25A levels decrease slowly after TGF-β treatment
suggesting that Cdc25A downregulation is a secondary event in the arrest of the cells in a quiescent
state. In HaCaT cells the decrease in Cdc25A levels is mediated by inhibitory complexes of E2F-4,
p130 and histone deacetylase (Iavarone and Massagué, 1999).
Downregulation of cyclin subunit seems not to be the major mechanism of Cdk inactivation by
TGF-β. TGF-β has been reported to decrease the cyclin D1 mRNA and protein levels (Table 2; Ko
et al., 1998; Flørens et al., 1996). In addition, TGF-β was found to decrease the amount of cyclin A
(Flørens et al., 1996). Since TGF-β arrests cells in late G1, prior the cell cycle point where cyclin A
increase normally occurs, the effect on cyclin A levels by TGF-β is probably secondary to the loss
of cyclin E-associated kinase activity needed for cyclin A mRNA synthesis (Zerfass-Thome et al.,
1997).
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A 4. Hepatocyte growth factor
Hepatocyte growth factor (HGF)/ Scatter factor induces growth, invasion, mobility and scattering
of epithelial cells (Nakamura et al., 1986, 1989; Stoker et al., 1987; Gherardi et al., 1989; Weidner
et al., 1990). Thus, the effects of HGF on epithelial cell growth are largely opposite to those of TGF-
β.
HGF is expressed predominantly in mesenchymal cells, whereas HGF receptor, the c-met proto-
oncogene, is found in epithelial and endothelial cells (Naldini et al., 1991a; Bussolino et al., 1992;
Birchmeier and Birchmeier, 1993; Sonnenberg et al., 1993). c-Met is a transmembrane receptor
tyrosine kinase (Naldini et al., 1991 b,c).
HGF mediates mesenchymal-epithelial signals during mouse development (Sonnenberg et al.,
1993; Schimdt et al., 1995; Uehara et al., 1995). HGF has been shown to stimulate several different
intracellular signaling pathways including phosphatidylinositol-3-kinase, Ras family members,
STAT and Smad leading to different kind of cellular responses. Activation of phosphatidylinositol-
3-kinase, Ras and Rac after HGF signal stimulates scattering and motility (Ridley et al., 1995; Royal
and Park, 1995), and Ras-pathway is stimulated during HGF induced cellular growth (Ponzetto et
al., 1996). During HGF induced epithelial tubulogenesis STAT pathway is induced (Boccaccio et
al., 1998). In addition, HGF has been shown to induce phosphorylation of Smad2 and its nuclear
translocalization (de Caestecker et al., 1998). However, the magnitude of the effects on Smad2
induced by HGF were less prominent than those by TGF-β, and the induction of Smad2 phosphorylation
by HGF was transient (de Caestecker et al., 1998).
A 5. Ras oncogene as a cellular growth regulator
Ras is an important regulator of eukaryotic cell growth. It is an intracellular membrane linked G-
protein, which can be activated in response to peptide growth factors, cytokines and hormones. One
of the best known intracellular Ras-signalling pathways involved in cellular proliferation is the Ras/
Raf/ERKs (extracellular signal-regulated kinases) cascade. Activated Ras stimulates the kinase
activity of Raf, which in turn activates the ERK kinases that are part of of the mitogen-activated
protein kinase (MAPK) pathway. Activation of this pathway leads to stimulation of various
transcription factors, such as Jun (reviewed by Hunter, 1997; Kerkhoff and Rapp, 1998; Vojtek and
Der, 1998).
Ras activity can lead to either induction or arrest of cellular proliferation. Mitogenic Ras activity
is required throughout the G1-phase, and it is essential for S-phase progression of fibroblasts
(Dobrowolski et al., 1994). It is suggested that Ras signal is mediated through pRb. Ras expression
induces activation of the Raf/MAPK pathway (Lavoie et al., 1996), upregulation of cyclin D mRNA
levels and it shortens G1-phase (Filmus et al., 1994; Liu et al., 1995; Winston et al., 1996). The
induced cyclin D levels lead to accumulation of active Cdk4/6-complexes and inactivation of pRb.
In addition, murine or rat fibroblasts treated with neutralizing antibodies against Ras, or expressing
a dominant-negative form of Ras fail to arrest when functional pRb is lacking (Leone et al., 1997;
Mittnacht et al., 1997; Peeper et al., 1997).
Another cell-cycle machinery protein linked to Ras/Raf pathway growth stimulation is p27 Cdki.
Overexpression of Ras and c-Myc in rat embryo fibroblasts leads to downregulation of p27 in a
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In addition to growth stimulatory effect, Ras can arrest the proliferation of primary rat Schwann
cells, pheochromocytoma cells, and rodent fibroblasts (Bar-Sagi and Feramisco, 1985; Franza et al.,
1986; Ridley et al., 1988; Benito et al., 1991), and induce cellular senescence of human diploid
fibroblasts and primary mouse fibroblasts (Serrano et al., 1997). It has been suggested that
constitutively active versions of Ras or Raf are growth inhibitory, whereas cellular proliferation
requires activation of Ras or Raf and an additional oncogene, or inactivation of a tumor suppressor.
Expression of activated Ras in primary mouse fibroblasts causes growth arrest and premature cellular
senescence that is associated with elevated levels of p53 and p16 (Serrano et al., 1997). In the absence
of p53 or p16 Ras expression allows transformation of the cells. Similarly, in the absence of Cdki
p21 (Missero et al., 1996; Michieli et al., 1996)
 
or in the presence of co-operative oncogenes such
as Myc (Land et al., 1983) Ras causes transformation. In addition, the strength and duration of Ras/
Raf signal seem to determine whether cells proliferate or differentiate. Pheochromocytoma PC12
proliferate as response to transient Ras/Raf signal, whereas the sustained activation causes these cells
to differentiate and eventually cease to proliferate (Qui and Greene, 1992). The differentiation of
PC12 was accompanied with elevated p21 Cdki levels (Yan and Ziff, 1995). Similarly, high levels
of Raf induce cell cycle arrest and p21, whereas in p21 deficient fibroblasts high Raf levels do not
arrest cellular growth (Sewing et al., 1997; Woods et al., 1997).
posttranscriptional manner, while expression of either Myc and Ras alone has no effect on p27
(Leone et al., 1997). In addition, downregulation of p27 levels by serum can be blocked by
overexpression of dominant negative Ras mutant (Aktas et al., 1997). These data suggest that Ras/
Raf pathway participitates in p27 regulation.
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B. AIMS OF THE PRESENT STUDY
This study was aimed at elucidating the regulation of cell cycle machinery proteins associated
with the TGF-β  induced G1 arrest of epithelial cells. Although the TGF-β signal transduction
pathway has been well studied, very little was known of how simultaneous inhibitory and stimulatory
signals are integrated. The finding that HGF releases Mv1Lu cells from TGF-β induced growth arrest
was used as a model to study the effects of TGF-β on endogenous cell cycle proteins. The detailed
aims of the study were:
1) to study the role of  p15 Cdki in TGF-β growth control,
2) to understand the mechanisms by which HGF allows cells to escape from TGF-β1 growth
arrest,
3) to study the effects of TGF-β and Ras oncoprotein on p27 and p21 Cdkis.
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C. MATERIALS AND METHODS
The cell lines, cDNA libraries, plasmid constructs, growth factors, antibodies and methods
used in this study are listed in the tables below.
Cell lines
Cell line Description Rerence or source Used in
COS-7 African green monkey ATCC I, IV
 kidney epithelial
DU-145 prostate carcinoma ATCC I
HaCaT human keratinocyte ATCC I
HeLa cervical carcinoma ATCC I
J-82 bladder carcinoma ATCC I
Mv1Lu mink lung epithelial ATCC I-III
NIH 3T3 mouse fibroblast-like, ATCC I, III-IV
 immortalized
SaOS-2 osteosarcoma ATCC I
SW-480 colon adenocarcinoma ATCC I
T-24 bladder carcinoma ATCC I
WI-38 human lung fibroblast ATCC I
NIH 3T3 NIH 3T3 stable transfected Kivinen et al., 1996 IV
 Ras clones  with pSVlacOras and
  pHβINLneo
Libraries and plasmids
Library/ plasmid Description Reference or source Used in
Human placental oligo d(T) primed in Clontech I
 cDNA library  λgt11 vector
pcDNA3 mammalian expression Invitrogen I
 vector with CMV promoter
pSG5 mammalian expression Stratagene  I, III
vector with SV40 promoter
pP10HA HA-tagged p10 cDNA from placental I
 cDNA in pcDNA3  cDNA library
pP10 p10 cDNA in pSG5 placental cDNA library I
pP15 p15 cDNA in pSG5 cDNA from HaCaT I
 cells
pP16 p16 cDNA in pSG5 cDNA from HeLa cells I
pP27 p27 cDNA in pSG5 cDNA from HaCaT III
 cells
pCdk2 Cdk2 cDNA in pRc/CMV Dr. Tomi Mäkelä, III
 University of Helsinki
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pCdk4 Cdk4 cDNA in pRc/CMV Dr. Tomi Mäkelä III
pCdk6 Cdk6 cDNA in pCMV Dr. J. LaBaer, Massachusetts III
 General Hospital
pCyclin E cyclinE cDNA in Dr. Tomi Mäkelä III
 pRc/CMV
pCyclin D1 cyclinD1 cDNA in Dr. Tomi Mäkelä III
 pRc/CMV
pCyclin D2 cyclinD2 cDNA in Dr. Tomi Mäkelä III
pRc/CMV
pSVlacOras Ha-ras under SV40/ Liu et al., 1992 IV
 lactose inducible promoter
pHβlacINLSneo lacI lactose repressor under Liu et al., 1992 IV
 β-actin promoter
pGEJ6.6 genomic Ha-ras in Mäkelä et al., 1992 IV
 pGEM7Zf(+)
p21 promoter constructs Datto et al., 1995b; IV
Kivinen et al., 1999
Growth Factors, Antibodies and Chemicals
Growth Factor/ Antibody/ Chemical Reference or source Used in
TGF-β1 human platelets I-III
HGF R&D Systems II
α-p15, rabbit or goat polyclonal (C-20) Santa Cruz I-II
α-p21, rabbit polyclonal (13436E) Pharmingen IV
α-p27, mouse monoclonal Transduction Laboratories II-IV
α-p27, rabbit polyclonal (C-19) Santa Cruz II-III
α-p27, rabbit polyclonal Dr. J. Massagué, Sloan- II-III
 Kettering Institute
α-Cdk2, rabbit or goat polyclonal (M2) Santa Cruz II-IV
α-Cdk4, rabbit polyclonal (C-22) Santa Cruz I-IV
α-Cdk6, rabbit polyclonal (C-21) Santa Cruz II-IV
α-Cdk6, mouse monoclonal (DCS-83) Dr. Jiri Bartek, Danish II-III
 Cancer Society
α-Cyclin E, rabbit polyclonal (M-20) Santa Cruz II
α-Cyclin E, rabbit polyclonal (06-459) Upstate Biotechnology II-III
α-Cyclin D1, rabbit polyclonal (H-295) Santa Cruz II-IV
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α-Cyclin D1, mouse monoclonal Dr. Jiri Bartek, Danish II-III
 (DCS-11)  Cancer Society,
α-Cyclin D2, rabbit polyclonal (C-17) Santa Cruz II-III
α-pRb, rabbit polyclonal (C-15) Santa Cruz II
α-p53, rabbit polyclonal  (Pab240) Pharmingen IV
α-Ras, mouse monoclonal (Ab-1) Oncogene Science IV
α-Sp1, mouse monoclonal (1C6) Santa Cruz IV
α-Sp3, rabbit polyclonal (D-20) Santa Cruz IV
α-HA, mouse monoclonal BabCo I
α-BrdUrd, mouse monoclonal Amersham Life Sciences II-III
α-BrdUrd, rat monoclonal Accurate Antibodies I
TRITC-conjugated α-mouse, rabbit DAKO I-III
 polyclonal
Cy3-conjugated α-mouse, donkey Jackson I
 polyclonal  Immunochemicals
Cy3-conjugated α-rabbit, donkey Jackson I
 polyclonal  Immunochemicals
FITC-conjugated α-rabbit, swine DAKO I
 polyclonal
FITC-conjugated α-rat, donkey Jackson I
 polyclonal Immunochemicals
Biotin-conjugated α-mouse, swine DAKO II-III
 polyclonal
Biotin-conjugated α-rabbit, swine DAKO II-III
 polyclonal
Peroxidase-conjugated α-mouse, DAKO IV
 rabbit polyclonal
Peroxidase-conjugated α-rabbit, DAKO IV
 swine polyclonal
PD 098059 Calbiochem IV
Calyculin A Calbiochem IV
Methods
Technique Used and described in
cDNA cloning and sequence analysis I
Screening of bacteriophage λ library I
RT-PCR I
Northern blot analysis I-II, IV
Southern blot analysis I
Western blot analysis II-IV
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Immunoprecipitation I-IV
Immunohistochemistry I-III
5-BrdUrd analysis I-III
Flow cytometry II
Cell transfection by calcium phosphate
 precipitation I, III-IV
Colony assay I
Metabolic labeling I-IV
Pulse-chase analysis II-IV
Kinase assays II-III
Phosphatase treatment III
Luciferase assay IV
EMSA IV
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D. RESULTS AND DISCUSSION
D 1. Cloning and characterization of p10, an alternative spliced form of p15 Cdk
inhibitor (I)
Ubiquitous expression and TGF-β regulation of p10 mRNA
After the cloning of p15 Cdki and the finding that it is regulated by TGF-β in HaCaT keratinocytes
(Hannon and Beach, 1994), we wanted to use the p15 cDNA in our studies concerning TGF-β growth
inhibitory mechanisms in Mv1Lu cells. In the process of cloning of p15 cDNA from human placenta
cDNA library using p16 exon 2 PCR product as a probe, a 2.3 kb cDNA was isolated. It contained
a novel 123 bp cDNA sequence flanked by exons 1 and 2 of p15. The 123 bp cDNA sequence, named
exon 1β, was identical to 5’ end of p15 intron 1 (Fig. 3; I: Fig. 1; Guan et al., 1994). In the 2.3 kb
cDNA exon 1 was not spliced to exon 2. Instead the cDNA contained exon 1 of p15 followed by exon
1β that was spliced to exon 2 by a new splice site downstream of that used in the splicing of exon
1 to exon 2 in p15. A stop codon at nucleotide position 554 in the exon 1β terminated the translation,
giving rise to a predicted 78 amino acid protein homologous to the p15 on its aminoterminal half but
lacking the p15 carboxyterminal half encoded by exon 2 sequence. Instead the protein, designated
as p10 based on the migration of an in vitro translation product in SDS-PAGE, contains a 25 amino
acid novel, basic carboxyterminal half, which lacks significant homology to known protein products.
p10 mRNA was found to be expressed in several normal and tumor cell lines including human
keratinocytes, fibroblasts, osteosarcomas, colon adenocarcinoma and bladder carcinomas when
exon 1β was used as a probe in Northern analysis (I: Fig. 2). Similarly to p15 (Hannon and Beach,
1994; Reynisdóttir et al., 1995), the p10 specific 5.2 and 7.4 kb mRNAs were upregulated in TGF-
β treated HaCaT cells (I: Fig. 3). The ubiquitous presence of p10 splice products suggests that at least
in cultured cell lines and in placenta the splicing takes place constitutively. In addition, the results
suggest that the p10 mRNAs share the same TGF-β1 regulatory promoter region as p15.
The subcellular localizations of transiently overexpressed p15 and HA-epitope-tagged p10 were
similar. In Mv1Lu cells both were found in cytoplasm and nucleus, whereas in NIH 3T3 cells they
localized predominantly to the cytoplasm (I: Fig. 4). Reynisóttir and Massagué (1997) have also
observed cytoplasmic and nuclear localization of exogenously expressed p15.
p10 does not associate with Cdks or cyclins
Since p15 is a Cdk inhibitor and involved in TGF-β induced G1 arrest (Hannon and Beach, 1994;
Reynisdóttir et al., 1995), we tested whether p10 is able to restrict cellular growth, and if so, is it due
to its association with Cdks or cyclins. However, stable overexpression of p10 in NIH 3T3 or Mv1Lu
cells had no effect on cellular growth as compared to colony formation of cells transfected with an
empty vector. As a control, p15 and p16 decreased the number of cell colonies by over 30% in NIH
3T3 cells (I: Table 2). Interestingly, stable expression of p15 in Mv1Lu cells did not decrease the
number of cell colonies, whereas p16 efficiently suppressed the growth (I: Table 2).
Unlike p15, p10 did not associated with Cdks. Immunoprecipitation analysis of overexpressed
p15, p10HA and Cdk4 in COS-7 cells indicated that anti-Cdk4 and -Cdk6 antibodies co-precipitated
p15 but not p10 (I: Fig. 5). In addition, expression of p10 in the cells did not prevent co-precipitation
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of p15 with either Cdk4 or Cdk6 antibodies suggesting that p10 does not compete with p15 for
interaction with these Cdks (I: Fig. 5). The exon 2 area that is not translated in p10, is almost totally
conserved (94% identity) in p15 and p16, and functionally relevant for binding to Cdk4/6 (Wick et
al., 1995; Fåhraeus et al., 1998; Luh et al., 1997; Russo et al., 1998). Thus our results, which suggest
that p10 is devoid of Cdk4 and Cdk6 interaction and, additionally, that it does not compete with p15
for interaction with the Cdks, were not unexpected.
We were unable to verify the existence of endogenous p10 protein by using p10 specific
antibodies for immunoprecipitations and western blotting analysis suggesting that either p10
specific mRNAs are not translated or that the protein levels of p10 are extremely low even in TGF-
β treated cells. p15 is not the only Cdki with multiple transcripts. p18 has at least four different
transcripts which are differentially expressed in various tissues (Guan et al., 1994; Hirai et al., 1995).
The regulation of the distinct mRNA forms is different in response to starvation or G1-S phase
transition (Hirai et al., 1995). p57 has two different sized mRNAs (Lee et al., 1995), and three
different cDNAs were isolated during p57 cloning (Lee et al., 1995; Matsuoka et al., 1995). The
shorter cDNA forms lack 13 amino acids from the N-terminus including the first translation initiator
codon, and they are started from a potential initiator codon downstream (Lee et al., 1995; Matsuoka
et al., 1995). However, there is no evidence that the shorter forms are translated (Lee et al., 1995).
The alternatively spliced form of p16, p14/19ARF, raises from usage of an alternative first exon with
a different promoter than that used for p16. In addition, p14/19ARF is translated in different reading
frame coding a non-Cdki protein (Duro et al., 1995; Mao et al., 1995; Quelle et al., 1995; Stone et
al., 1995b). Instead, p14/19ARF is involved in the p53 regulation (reviewed by Sherr, 1998).
D 2. HGF releases Mv1Lu cells from TGF-β induced G1 arrest by restoring Cdk6
expression and Cdk2 activity (II)
The finding that HGF releases Mv1Lu cells from TGF-β growth inhibition (Taipale and Keski-
Oja, 1996) gave us a good model system to study the separate and simultaneous effects of a growth
inhibitory growth factor (TGF-β) and a stimulatory growth factor (HGF) on endogenous cell cycle
machinery proteins.
HGF decreased the number of Mv1Lu cells arrested in G1 phase by TGF-β as indicated by flow
cytometry and 5-BrdUrd incorporation analyses (II: Fig. 1). Most of pRb was found in phosphorylated
forms after treatment of the cells with both growth factors, which is in line with the four-fold increase
in DNA synthesis in cells treated with both TGF-β and HGF as compared to TGF-β treated cells (II;
Fig. 1 and 2). As TGF-β is a very potent growth inhibitor of Mv1Lu cells (ED50 = 5 pM), the rescue
from TGF-β growth arrest by HGF was significant, albeit not complete.
HGF counteracts the effects of TGF-β on Cdk6 protein level and complex formation with
cyclin D2 and p27, but not on p15 induction
pRb is phosphorylated in G1 by cyclin D complexes (Kato et al., 1993; Connell-Crowley et al.,
1997; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 1998). To study how HGF
signaling interacts with TGF-β signaling to prevent the shift of pRb to its underphosphorylated form,
we analyzed the effects of TGF-β and HGF on the levels on G1 Cdks and their complexes.
Interestingly, TGF-β decreased the expression of Cdk6 and its association with cyclin D2, whereas
HGF prevented these effects (II: Fig. 3A and 4A). Additional studies suggested that TGF−β had no
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effect on the Cdk6 mRNA levels (II: Fig. 3C). Instead TGF−β decreased the synthesis and increased
the turnover of Cdk6, whereas HGF opposed both of these effects (II: Fig. 3B and D).
Despite that HGF antagonized the TGF−β induced growth arrest, it did not prevent the TGF−β-
mediated induction of p15 or its complex formation with Cdk6 (II: Fig. 3A and 4A). Upon TGF−
β treatment the association of Cdk6 with cyclin D2 was decreased, as well as the binding of p27 to
Cdk6. The results reflect the presence of lesser amounts of Cdk6 in the TGF−β-treated cells as well
as displacement of p27 from Cdk6-complexes by p15 as suggested earlier (Reynisdóttir et al., 1995).
HGF restored the association of Cdk6 with cyclin D2 and Cdk6 binding to p27 in cells treated with
both growth factors (II: Fig. 4A).
The restoration of Cdk6 expression in cells treated with both growth factors correlated with the
partial rescue of the cyclin D2-associated kinase activity towards GST-Rb (II: Fig. 4B). This
suggests that though p15 induction is unperturbed in cells treated with both growth factors and it
forms avidly complexes with Cdk6, its levels are not high enough to fully prevent the activity of
Cdk6-cyclin D2 complexes. In addition, the levels of p15 may not be sufficient to sequester all Cdk6
present in the cells. This in turn leads to the presence of active Cdk6-cyclin D2-complexes that can
harvest p27 from binding to Cdk2. Thus, the decrease in Cdk6 expression may contribute an
important part to the induction, maintenance and adaptation of the cells to the TGF−β-mediated
growth arrest. However, since HGF could only partly rescue the cyclin D2-associated kinase activity,
HGF may also override the TGF−β block by mechanisms other than solely regulation of the G1
cyclin-Cdk complexes.
HGF counteracts TGF−β regulation of Cdk2-cyclin E activity
Cdk2-cyclin E-complexes phosphorylate pRb in the late G1-phase (Akiyama et al., 1992;
Lundberg and Weinberg, 1998). In accordance with the earlier studies, we found that TGF−β
treatment enhanced the association of p27 to Cdk2-cyclin E-complexes (II: Fig.5B; Polyak et al.,
1994a, b; Reynisdóttir et al., 1995; Reynisdóttir and Massagué, 1997; Sandhu et al., 1997).
Concomitantly, TGF−β decreased the amount of the faster migrating, active form of Cdk2 (II: Fig.
5A; Koff et al., 1993; Reynisdóttir et al., 1995). Both these events lead to a decrease in Cdk2- and
cyclin E-associated kinase activities (II: Fig. 6A and B; Koff et al., 1993; Polyak et al., 1994a, b;
Reynisdóttir et al., 1995; Reynisdóttir and Massagué 1997). When the cells were treated with both
growth factors, the TGF−β-mediated decrease in the faster migrating form of Cdk2 was efficiently
prevented by HGF, although HGF could not prevent the induction of p27 association with cyclin E
or Cdk2 (II: Fig. 5A and B). HGF also restored the TGF−β suppressed Cdk2 and Cyclin E-associated
kinase activities towards Histone H1 and GST-Rb, which is in line with the observed phosphorylation
status of pRb (II: Fig. 6A and B).
The observed  Cdk2 and cyclin E-associated kinase activity in cells treated with both growth
factors could result from complexes devoid of p27. The possibility was addressed by immunodepletion
analyses using polyclonal anti-p27 antibodies. The depletion steps did not significantly affect on the
total levels of cyclin E or Cdk2 (II: Fig. 7B). However, all cyclin E−bound Cdk2 present in TGF−
β-treated cells was removed. Instead, in cells treated with both growth factors, 30% of cyclin E-
bound Cdk2 was left after immunodepletion, suggesting that less p27 remains attached with cyclin
E/Cdk2 complex. Histone H1-kinase assays, carried out in parallel with the above experiment,
indicated that TGF−β decreased the cyclin E-associated kinase activity to close to basal levels in both
p27-depleted and non-depleted lysates (II: Fig. 7A). Depletion of p27 from cells treated with both
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growth factors had no effect on the activity. The p27-depletion assays suggest that though p27 is
associated with Cdk2-cyclin E-complexes in cells treated with both TGF−β and HGF and part of
these complexes are removed, there appears to be enough active complexes present in the cells
sufficient for cellular proliferation.
HGF is able to induce proliferation of cells that have been growth arrested by TGF−β
HGF was found to bypass the TGF−β-mediated growth arrest also under conditions in which the
cells were first arrested into G1 by TGF−β followed by addition of HGF without the removal of TGF−
β. HGF increased the amount of the DNA synthesis after 12 h of addition of HGF, and significant
amount of the cells replicated their DNA after 24 h of HGF addition (II, Fig. 6C). In contrast, serum
stimulation of TGF−β arrested cells was without effect on DNA replication. Analyses on Cdk6 and
Cdk2 indicated that HGF restored expression of Cdk6 and the faster migrating form of Cdk2 with
kinetics that paralleled entry of the cells into S-phase. Similarly the Cdk2-associated kinase activity
was restored. The results suggest that HGF releases Mv1Lu cells from TGF−β-mediated growth
arrest with concomitant upregulation of Cdk6 and increased Cdk2-cyclin E activities.
Our results suggest that HGF modifies the TGF−β response by regulation of Cdk6-complexes and
as a consequence affects the activity of Cdk2-complexes, and that both these events serve as means
to hinder the growth inhibition induced by TGF−β. In this manner the effect of HGF on TGF−β
induced growth arrest is different than that of viral oncoproteins such as SV40, E1A or E7, which
sequester and inactivate pRb thus bypassing the requirement of Cyclin D-associated kinase activity
(Whyte et al.,  1988; DeCaprio et al.,  1988; Dyson et al.,  1989; Munger et al.,  1989; Egan et al.,
1989). However, E1A also prevents the induction of p15 and p21 by TGF−β (Datto et al., 1997).
Similarly, E1A and E7 bind to and sequester p27 from Cdk2-cyclin E complexes which leads to
activation of the complex (Mal et al., 1996; Zerfass-Thome et al., 1996). This suggests that activation
of at least Cdk2-complexes is required in addition to pRb inactivation to ensure cell cycle
progression.
Fig. 6 Schematic model of how
HGF prevents TGF-β growth ar-
rest in Mv1Lu cells. HGF prevents
the downregulation of Cdk6 by
TGF-β leading to increased
amounts of Cdk6-cyclin D2-p27
complexes that are active. Since
HGF is unable to prevent
upregulation of the p15 Cdk in-
hibitor, there are still inactive
Cdk6-complexes present. In addi-
tion, less p27 is liberated from
Cdk6 complexes than in TGF-β
treated cells leading to accumula-
tion of p27-free Cdk2-cyclin E-
complexes. This, together with the
similar amounts of thr-
phosphorylated Cdk2 as in
exponentially growing cells, leads
to increased Cdk2 kinase activity.
Cdk6 kinase activity together with
that of Cdk2 allows cell cycle pro-
gression.
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Based on our results we suggest a model, in which regulation of Cdk6 levels serves as means to
regulate both Cdk6- and Cdk2-activities (Fig. 6). The upregulation of p15 and subsequent relocalization
of p27 are not enough to prevent cellular proliferation as suggested by the treatment of the cells with
both growth factors. The downregulation of Cdk6 levels and presence of an active form of Cdk2 are
also required. The release of Cdk2-cyclin E-activity from suppression by p27 occurs as a secondary
mechanism through increased binding of Cdk6-complexes to p27. The hypothesis that TGF−β
growth arrest involves additional mechanisms besides action of p15 and p27 Cdkis is strengthened
by genetic and biochemical evidence, as cells from mice nullizygous for p27 (Nakayama et al., 1996)
and mammary epithelial cells that lack p15 (Iavarone and Massagué, 1997), are growth inhibited by
TGF−β. These models imply that for growth suppression TGF−β must affect multiple cell cycle
components. Interestingly, also p16 growth arrest requires the co-operation of p27. Dominant
negative Cdk4 that associates with cyclin D forming inactive kinase complexes is unable to arrest
growth of U2OS cells when overexpressed (van den Heuvel and Harlow, 1993). In contrast,
overexpression of p16 in U2OS cells leads to G1 arrest due to inactivation of Cdk4 by p16 and Cdk2-
complexes by p27 (Jiang et al., 1998). p27 is liberated from cyclin D-complexes by p16 suggesting
that inactivation of cyclin D-associated kinase activity is not sufficient for G1 arrest (Jiang et al.,
1998; McConnell et al., 1999).
Furthermore the present data indicates that the positive and negative growth signals are integrated
at the level of Cdk-regulation. Little is known of how cells respond to simultaneous inhibitory and
stimulatory growth factors, and on what level these signals are integrated. Recent data suggest that
they can be integrated by intracellular signaling pathways. Epidermal growth factor and HGF can
antagonize the effects of bone morphogenetic protein by inducing phosphorylation of Smad1 via the
extracellular signal-regulated kinase mediated pathway. The phosphorylation leads to the inhibition
of bone morphogenetic protein signaling (Kretzschmar et al., 1997), suggesting that opposing
signals are modulated at the level of Smad proteins. Smad1 is not involved in TGF−β signaling
(Massagué, 1996), but similar mechanisms utilizing Smad2 and 3 could affect the ability of HGF to
alter the growth inhibitory effect by TGF−β. Indeed, recent work shows that HGF can phosphorylate
and activate Smad2, although to a lesser extent than TGF−β (de Caestecker et al., 1998). In addition,
IFN-g was shown to prevent the induction of 3TP-luc reporter by TGF−β. 3TP-luc contains TGF−
β responsive elements from the plasminogen-activator inhibitor-1 gene. IFN-γ induces inhibitory
Smad7 via the Jak/Stat pathway and prevents TGF−β signal transduction (Ulloa et al., 1999). Our
data, however, indicates that HGF does not inhibit, nor act synergistically with TGF−β signal
transduction, because HGF does not alter the level of induction of p15 or extracellular matrix
components such as fibronectin and thrombospondin (Taipale and Keski-Oja, 1996) or PAI-1 (not
shown) by TGF−β. Our results are consistent with the hypothesis that HGF does not interfere, in
general, with the TGF−β signal transduction pathways, but that the signals involving growth
regulation are integrated at the level of Cdk complexes.
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D 3.  TGF-β induces accumulation of a nuclear p27Kip1 form devoid of Cdk-cyclin-
association (III)
TGF-β and growth arresting treatments induce accumulation of a nuclear form of p27
TGF-β has been reported to have no effect on the total p27protein levels in Mv1Lu cells (Polyak
et al., 1994b). However, in the course of the study II we found out that in TGF-β treated Mv1Lu cells
a specific form of p27 accumulated. The accumulated p27 form was found by immunoprecipitations
using a specific monoclonal antibody (p27 mAb from Transduction Laboratories) (III: Fig. 1A). In
addition to TGF-β treated cells, the accumulated p27 form was detected in Mv1Lu cells growth
arrested by low serum or contact inhibition suggesting that the accumulation is not only due to TGF-
β treatment, but associates with G0/G1  arrest (III: Fig. 1A). No regulation of p27 levels was detected
when using a polyclonal p27 antibody (p27 pAb) for immunoprecipitation. Similarly, total p27 levels
were not affected by TGF-β or low serum treatments, which is in accordance with earlier studies (III:
Fig. 1B; Reynisdóttir et al., 1995; Sandhu et al., 1997). The levels of p27 immunoprecipitated from
TGF-β treated cells with p27 mAb antibody were found to be induced also in metabolically labeled
cells (III: Fig. 1) suggesting that the induction, at least partly, requires protein synthesis. However,
since there is no change in the total p27 protein or mRNA levels in the TGF-β-treated Mv1Lu cells
(III: Fig. 1B; Polyak et al., 1994b; data not shown), the observed increase in the metabolic labeled
lysates could reflect change in p27 conformation or complexes. Furthermore, the amount of p27
precipitated by the p27 mAb in TGF-β-treated cells was consistently lower than the amount of p27
precipitated by the p27 pAb (III: Fig. 1A, compare lanes 2 and 4), suggesting that the TGF-β-
inducible p27 represents a fraction of total p27 present in the cells.
p27 localizes predominantly to nucleus (Lee et al., 1996; Reynisdóttir and Massagué, 1997;
Orend et al., 1998; Singh et al., 1998; Tomoda et al., 1999). The accumulated p27 form recognized
by the p27 mAb was found only in nuclei of growth arrested Mv1Lu and NIH 3T3 cells, whereas NIH
3T3 cells that are growth stimulated by TGF-β (Pitkänen et al., 1993) lacked completely p27 staining
with the p27 mAb (III: Fig. 2A and B). In contrast, the p27 pAb detected p27 similarly in both control
and growth arrested Mv1Lu and NIH 3T3 cells (III: Fig. 2A and B). In the TGF-β treated NIH 3T3
cells the amount of p27 positive nuclei, as detected by the p27 pAb, was somewhat decreased. The
results suggest that TGF-β and treatments arresting the cells in G0/G1 induce a form of p27 that can
be detected in individual cells at high levels with exclusive nuclear localization. That in NIH 3T3
fibroblasts stimulated to proliferate by TGF-β the accumulated p27 form was excluded from the
nucleus further verifies that the inducible p27 is sensitive to the growth status of the cells. It also
suggest that the p27 form recognized by the p27 mAb is either not present or is in different kind of
complexes in growth stimulated than in growth arrested cells.
The TGF-β inducible form of p27 is a subpopulation of the total p27 pool, but does not
associate with Cdk-cyclin complexes
The results using either monoclonal or polyclonal p27 antibodies in the above assays suggested
that the monoclonal antibody could recognize a subpopulation of the total p27 pool recognized by
the polyclonal antibody. The possibility was verified by immunodepletion assay showing that
immunodepletion with the p27 pAb removed all detectable p27 from control and TGF-β treated cells
(III: Fig. 3A). The p27 mAb removed some of p27 from TGF-β treated lysates but none of the protein
from the control lysates (III: Fig. 3A). When the lysates were denaturated with 1% SDS and boiling
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prior to the immunoprecipitations, the p27 mAb immunoprecipitated similar amounts of p27 from
control and TGF-β treated cells (III: Fig. 3B). The result suggests that upon denaturation the p27
mAb recognizes the total p27 protein pool as shown also by the western blotting analyses of total cell
lysates. We also found that phosphorylation of p27 had no effect on the antibody recognition (III:
Fig. 3C). The results suggest that the p27 mAb recognizes a native TGF-β inducible form of p27,
which represents a subpopulation of the total p27 pool present in the cells.
The half-lives of different p27 pools detected by the mAb and pAb antibodies were compared with
a pulse-chase experiment. p27 half-life in proliferating human fibroblasts has been reported to be
approximately 50 min, and six times longer in quiescent cells (Pagano et al., 1995). Similarly, TGF-
β increased the half-life of p27 recognized by the p27 pAb from less than two hours to over six hours
(III: Fig. 4). The half-life of the TGF-β inducible form of p27 was found to be three hours. These
findings suggest that the half-life of the TGF-β inducible form of p27 is significantly shorter than that
of p27 recognized by the p27 pAb in TGF-β-treated cells. A shorter half-life for the TGF-β-inducible
p27 may suggest either its faster degradation or conversion to a form not recognized by the antibody.
p27 binds to cdc2, Cdk2, 4 and 6 complexes (Polyak et al., 1994b; Toyoshima and Hunter, 1994).
However, we found out that the p27 mAb did not co-immunoprecipitate any of Cdks 2, 4 or 6 or
cyclins E or D1-2 or Cdc2 from endogenous lysates (III: Fig. 5; data not shown) or from lysates that
were overexpressing p27 together with Cdks 2, 4 or 6 and cyclin E, D1 or D2 (III: Fig. 6; data not
shown). In contrast, the p27 pAb co-immunoprecipitated all the mentioned Cdks and cyclins (III:
Fig. 5 and 6; data not shown). Furthermore, epitope mapping of the p27 mAb indicated that the p27
mAb recognizes a p27 domain spanning amino acids 1 to 91, which harbors the Cdk and cyclin
interaction domains of p27 (Polyak et al., 1994b; Toyoshima and Hunter, 1994). The p27 pAb
recognizes an epitope mapping to the carboxyterminal amino acids 181-198. Taken together, these
findings suggest that the TGF-β inducible form of p27 is not associated with Cdks 2,4 or 6 or with
cyclins D1-2 or E.
In accordance with the above results, the p27 mAb did not co-immunoprecipitate any kinase
activity towards GST-Rb or histone H1 (III: Fig. 5). Instead, the p27 pAb co-immunoprecipitated
kinase activity both from control and TGF-β treated cells (III: Fig. 5). The GST-Rb kinase activity
can, at least partly, be attributed to co-precipitation of Cdk4/6-cyclin D complexes, as p27 has been
found not to block the activity of this complex (Poon et al., 1995; Soos et al., 1996; Hauser et al.,
1997; Blain et al., 1997, Dong et al., 1998). The presence of histone H1 kinase activity may result
from the presence of active Cdk2 complexes in p27 immunoprecipitates, since Cdk4 or 6 do not
utilize histone H1 as a substrate (Matsushime et al., 1994). Cdk2 has been shown to associate with
cyclins D2 and 3 in Sf9 insect cells and to phosphorylate histone H1 (Matsushime et al., 1994).
However, there is no evidence that Cdk2 can form complexes with D-type cyclins in Mv1Lu cells,
or that these complexes could phosphorylate histone H1.
TGF-β modulates cellular growth by regulating the availability and association of Cdkis with the
Cdk-cyclin complexes. Our data indicated that part of the p27 pool is not associated with Cdk-cyclin
complexes after TGF-β and other growth arresting treatments. The lack of p27 staining with the p27
mAb in TGF-β growth stimulated NIH 3T3 cells suggest that in exponentially growing cells all p27
is associate with Cdk or possible other cellular complexes. The induction of p27 in metabolically
labeled samples, at least in part, could be due to increased synthesis of the protein. However, a major
part, if not all, could represent p27 released from Cdk4/6-complexes by the action of p15
(Reynisdóttir and Massagué, 1997; Sandhu et al., 1997) and by the downregulation of Cdk6 levels
(II; Fig. 3 and 4) induced by TGF-β. Together with the finding that in TGF-β treated cells Cdk2-
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D 4. Ras induces the p21 Cdk inhibitor both transcriptionally and posttranscriptionally
(IV)
The p21 Cdk inhibitor has been shown to be induced by Ras and its signal mediator Raf (Lloyd
et al., 1997; Sewing et al., 1997; Woods et al., 1997; Olson et al., 1998). However, the level of p21
regulation was not known. For this reason, we undertook analysis of p21-regulation by Ras in NIH
3T3 fibroblasts that express c-Ha-Ras under an inducible lactose promoter. The expression of Ras
is induced by inactivating the lactose repressor with the lactose analog IPTG.
Conditional Ras expression increases p21 protein levels
As p21 is regulated both transcriptionally and posttranscriptionally (Liu et al., 1996; Macleod et
al., 1995; Schwaller et al., 1995; Zeng and El-Deiry, 1996), we analyzed the effects of conditionally
expressed Ras on p21 protein and mRNA levels. Three Ras clones (ras 8, 22 and 30) with the highest
Ras induction levels were chosen for the studies. Northern blotting experiments revealed a slight
increase in basal expression of p21 mRNA in the Ras clones as compared to non-transfected NIH 3T3
cells and neo clones (mean induction 1.6-fold; IV: Fig. 5A). Similarly, p21 mRNA was only slightly
increased by Ras expression (IV: Fig. 5A).
The basal protein levels of p21 were found to be increased in all three Ras clones by western
blotting analysis (IV: Fig. 1A, middle panel). Moreover, induction of Ras expression with IPTG
significantly induced p21 expression in the Ras clones with kinetics that paralleled the induction of
Ras (IV: Fig. 1B). In addition, increased levels of p21 were found to associate with Cdk2 and 4
complexes after Ras induction (IV: Fig. 2C). Also the amounts of the immunoprecipitable cyclin D
and Cdk4-associated cyclin D increased after IPTG treatment (IV: Fig. 2), which is in agreement with
earlier studies (Winston et al., 1996). However, although Ras expression increased p21 in Cdk2 and
Cdk4 complexes, the level of p27 was unaltered by Ras in the exponentially growing cells, or in the
complexes with Cdk2 or 4 (IV: Fig. 2A and D). These results are concordant with earlier data that
Ras alone is unable to affect p27 levels, but that joint expression of Ras and Myc, or additional growth
factor stimulation is needed for this effect (IV: Fig. 2; Leone et al., 1997; Winston et al., 1996). In
additon, the levels of p53, the best known regulator of p21, were not affected by Ras induction (IV:
Fig. 1A).
Since the p21 protein levels were increased after Ras induction, we analyzed the effect of Ras on
p21 protein synthesis and half-life by metabolic labeling of ras8-cells. Ras expression increased the
amount of newly synthesized p21 protein by 2.5-fold (IV: Fig. 3, lanes 2 and 8). However, induction
of Ras had no effect on the p21 protein half-life (IV: Fig. 3). Taken together, the results suggest that
p21 induction by conditional Ras expression occurs mainly via increase in p21 protein synthesis.
cyclin E complexes are saturated with p27 (II; Fig. 7B), the data suggest that TGF-β releases more
p27 from cyclin D-complexes that can be absorbed to Cdk2-cyclin E-complexes. In this manner the
TGF-β-inducible p27 may serve as a reservoir, the binding of which to Cdk2-cyclin E/A facilitates
the establishment of cell cycle arrest.
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Sp1-transcription factors mediate the transcriptional activation of p21 by Ras
To investigate possible transcriptional activation of p21 by Ras, a luciferase activity assay was
carried out in COS-7 and NIH 3T3 cells transiently transfected with Ha-Ras together with a 2.4 kb
p21-promoter luciferase construct (p21p). As compared to controls transfected with pCDneo, Ras
increased the activity of p21 2.4 kb promoter by 6.0- and 7.6-fold in COS-7 and NIH 3T3 cells,
respectively, indicating that Ras can induce p21 transcriptionally (IV: Fig. 6A-B). However,
transfection of the 2.4 kb (p21p) or 93 bp (93-S) p21 promoter constructs to ras8-cells and induction
of Ras expression by IPTG had no major effect on the luciferase activity further suggesting that in
ras8 clones p21 induction is regulated at the posttranscriptional level (IV: Fig. 6C).
For more close mapping of the Ras responsive element we used a series of deletion or mutation
constructs based on the 2.4 kb p21-promoter in the luciferase assay (IV: Fig. 7 and Datto et al.,
1995b). Experiments using the deletion constructs suggest that that the Ras responsive region in p21
promoter spans between -110 and -62 bp relative to the transcription start site (IV: Fig. 6A-B). This
area in human p21 promoter carries three GC-rich Sp1-binding sites (numbered 1-3 in IV: Fig. 7),
the second of which overlaps with a TGF-β responsive element (TβRE; IV: Fig. 7) (Datto et al.,
1995b). Two additional Sp1-sites are located close to the TATA-box, between -61 to -50 (Sp1-
binding sites 4 and 5; IV: Fig. 7). Mutations of the Sp1 binding sites or TβRE decreased the overall
basal luciferase activity. However, none of the mutations alone could totally abolish the transcrip-
tional induction by Ras, although loss of Sp1 binding site 2 or TβRE decreased the Ras induction (IV:
Fig. 7). The Ras induction was completely lost when both of the Sp1-binding sites 2 and 4 were
mutated simultaneously (IV: Fig. 7). The activation was absent also in construct Sma∆1 containing
the Sp1-binding site 4, suggesting that intact Sp1-binding site 2 (or TβRE) is required for the function
of the Sp1-binding site 4, and indicating a critical role for interactions between transcription factors
acting in different regions for full promoter activity. Similarly, induction of p21 during keratinocyte
differentiation or by progesterone is dependent on correct spacing of the promoter elements (Owen
et al., 1998; Prowse et al., 1997). The mutant construct that affects the TβRE but does not eliminate
any of the Sp1-binding sites (mut 2.3) (Datto et al., 1995b), showed a weaker induction of luciferase
activity by Ras similarly to the mutants affecting the Sp1-binding site 2 and TβRE simultaneously
(mut 2 and mut 2.2). This could refer to the relevance of TβRE as well as the Sp1-binding site 2 in
the Ras effect.
Binding of two closely related transcription factors Sp1 and Sp3 to the Sp1-binding site 2/ TβRE
was characterized earlier (Datto et al., 1995b). Our results indicated that in NIH 3T3 cells Sp3, but
not Sp1 transcription factor is associated with this region (IV: Fig. 8C). However, in COS-7 cells
antibodies against these transcription factors caused supershift in an EMSA assay (IV: Fig. 8B)
indicating the presence of both Sp1 and Sp3 proteins. The results thus suggest that depending on
cellular context, either both Sp1 and Sp3 or Sp3 alone bind the Sp1-binding site 2/ TβRE region. Sp1
transcription factors have been regarded as house-keeping transcription factors. Recently, however,
the Sp1 family has been implicated in the induction of p21 by TGF-β (Datto et al., 1995b; Li et al.,
1998), okadaic acid and phorbol esters (Biggs et al., 1996), NGF (Yan and Ziff, 1997), and
progesterone (Owen et al., 1998), as well as in differentiation of keratinocytes (Prowse et al., 1997).
The DNA-binding of Sp1 and Sp3 was not affected by Ras, and was unaltered also upon p21
induction by TGF-β or NGF (Datto et al., 1995b; Yan and Ziff, 1997) suggesting that the
transactivation function of these factors is enhanced by mechanisms other than regulation of Sp1 and
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Sp3 protein levels or DNA-binding activity. Alternatively, the Ras effect could (also) be mediated
by other transcription factors associating with the same promoter region.
Taken together, the data suggest the presence of both transcriptional and posttranscriptional
components in the Ras-regulation of p21 that may be determined by the level and/ or duration of Ras
expression. Although there is no marked induction of p21 mRNA levels in NIH 3T3 cells
conditionally expressing Ras, there is a clear induction of p21 promoter activity in COS-7 and NIH
3T3 cells transiently transfected with Ras. The transcriptional p21 regulation by additional induction
of Ras in constitutively Ras expressing cells with higher basal level of Ras may be attenuated (or
absent). Transcriptional induction of p21 by Ras may thus depend on the level or duration of Ras-
expression, and after reaching a certain threshold transcriptional regulation may be switched to
posttranscriptional.
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E. CONCLUDING REMARKS
TGF-β has previously been shown to inhibit G1 and G1/S specific Cdk-cyclin-complex activities
by several different mechanisms including regulation of the complex formation with different Cdk
inhibitors, phosphorylation and downregulation of the Cdk-subunit. This study identifies novel ways
of regulation of G1 and G1/S specific Cdk-cyclin complexes. Our work suggest that TGF-β growth
arrest in Mv1Lu cells requires downregulation of Cdk6 levels in addition to p15 and p27 Cdki
accumulation leading to concomitant loss of Cdk6- and Cdk2-activity (II). In addition, our data
suggest that upregulation (or stable overexpression) of p15 alone is not enough to prevent growth of
Mv1Lu cells (I-II). We also found that TGF-β induces accumulation of a p27 form that is not
associated with Cdks (III), and that p15 Cdk inhibitor has an alternatively spliced form that is induced
by TGF-β treatment (I). In addition, we found that overexpression of Ras-oncogene induces p21 Cdk
inhibitor, but not p27 Cdki (IV).
These findings support the idea that TGF-β growth inhibition involves regulation of Cdk-
complexes at multiple levels. Initiation of TGF-β growth inhibition in Mv1Lu cells may be due to
induction of p15 Cdk inhibitor, which occurs within a couple of hours after TGF-β has been added
to cells. The decrease in Cdk6 levels provides an additional mechanism by which a growth inhibitory
status is induced and maintained. Together the increase in p15 levels and the decrease in amount of
Cdk6 inhibit cyclin D-associated kinase activity. In addition, the TGF-β treatment prevents Cdk2
activity by re-localizing p27 into Cdk2-complexes and by blocking the activating phosphorylation
of Cdk2. The accumulation of p27 found in study III could form a buffer to ensure that all Cdk2 (and
Cdc2)-associated kinase activity is kept inactive.
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